WO2021160109A1 - 二氢萘啶酮类化合物,其制法与医药上的用途 - Google Patents
二氢萘啶酮类化合物,其制法与医药上的用途 Download PDFInfo
- Publication number
- WO2021160109A1 WO2021160109A1 PCT/CN2021/076160 CN2021076160W WO2021160109A1 WO 2021160109 A1 WO2021160109 A1 WO 2021160109A1 CN 2021076160 W CN2021076160 W CN 2021076160W WO 2021160109 A1 WO2021160109 A1 WO 2021160109A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- alkyl
- membered
- substituted
- ring
- Prior art date
Links
- -1 Dihydronaphthyridinone compound Chemical class 0.000 title claims abstract description 142
- 238000002360 preparation method Methods 0.000 title claims abstract description 37
- 150000001875 compounds Chemical class 0.000 claims abstract description 76
- 102100022501 Receptor-interacting serine/threonine-protein kinase 1 Human genes 0.000 claims abstract description 31
- 150000003839 salts Chemical class 0.000 claims abstract description 31
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 25
- 239000000651 prodrug Substances 0.000 claims abstract description 25
- 229940002612 prodrug Drugs 0.000 claims abstract description 25
- 201000010099 disease Diseases 0.000 claims abstract description 18
- 101001109145 Homo sapiens Receptor-interacting serine/threonine-protein kinase 1 Proteins 0.000 claims abstract description 13
- 239000012453 solvate Substances 0.000 claims abstract description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 11
- 239000003814 drug Substances 0.000 claims abstract description 6
- 229940079593 drug Drugs 0.000 claims abstract description 5
- 125000000217 alkyl group Chemical group 0.000 claims description 361
- 229910052757 nitrogen Inorganic materials 0.000 claims description 207
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 164
- 125000001424 substituent group Chemical group 0.000 claims description 144
- 125000002950 monocyclic group Chemical group 0.000 claims description 129
- 229910052739 hydrogen Inorganic materials 0.000 claims description 121
- 239000001257 hydrogen Substances 0.000 claims description 121
- 125000001072 heteroaryl group Chemical group 0.000 claims description 111
- 125000003545 alkoxy group Chemical group 0.000 claims description 94
- 229910052736 halogen Inorganic materials 0.000 claims description 94
- 150000002367 halogens Chemical class 0.000 claims description 94
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 86
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 73
- 150000002431 hydrogen Chemical class 0.000 claims description 70
- 125000004432 carbon atom Chemical group C* 0.000 claims description 69
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 69
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 69
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 68
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 63
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 62
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 59
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 55
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 52
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 claims description 51
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 48
- 125000002619 bicyclic group Chemical group 0.000 claims description 48
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 47
- 229910052805 deuterium Inorganic materials 0.000 claims description 47
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 46
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 46
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 44
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 42
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 41
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 40
- 125000001475 halogen functional group Chemical group 0.000 claims description 39
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 37
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 35
- 229920006395 saturated elastomer Polymers 0.000 claims description 35
- 125000003118 aryl group Chemical group 0.000 claims description 33
- 125000006578 monocyclic heterocycloalkyl group Chemical group 0.000 claims description 32
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims description 30
- BGTOWKSIORTVQH-UHFFFAOYSA-N cyclopentanone Chemical compound O=C1CCCC1 BGTOWKSIORTVQH-UHFFFAOYSA-N 0.000 claims description 30
- QWENRTYMTSOGBR-UHFFFAOYSA-N 1H-1,2,3-Triazole Chemical compound C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 claims description 28
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 claims description 28
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims description 28
- JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 claims description 28
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 claims description 28
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 claims description 26
- 238000006467 substitution reaction Methods 0.000 claims description 25
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 claims description 24
- 125000004043 oxo group Chemical group O=* 0.000 claims description 23
- NDOVLWQBFFJETK-UHFFFAOYSA-N 1,4-thiazinane 1,1-dioxide Chemical compound O=S1(=O)CCNCC1 NDOVLWQBFFJETK-UHFFFAOYSA-N 0.000 claims description 21
- 230000004927 fusion Effects 0.000 claims description 21
- 229910052760 oxygen Inorganic materials 0.000 claims description 21
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 20
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 claims description 20
- 125000001731 2-cyanoethyl group Chemical group [H]C([H])(*)C([H])([H])C#N 0.000 claims description 19
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 claims description 19
- 125000006574 non-aromatic ring group Chemical group 0.000 claims description 19
- RAOIDOHSFRTOEL-UHFFFAOYSA-N tetrahydrothiophene Chemical compound C1CCSC1 RAOIDOHSFRTOEL-UHFFFAOYSA-N 0.000 claims description 19
- ARGCQEVBJHPOGB-UHFFFAOYSA-N 2,5-dihydrofuran Chemical compound C1OCC=C1 ARGCQEVBJHPOGB-UHFFFAOYSA-N 0.000 claims description 18
- RSEBUVRVKCANEP-UHFFFAOYSA-N 2-pyrroline Chemical compound C1CC=CN1 RSEBUVRVKCANEP-UHFFFAOYSA-N 0.000 claims description 18
- 125000004429 atom Chemical group 0.000 claims description 18
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 claims description 17
- 125000005843 halogen group Chemical group 0.000 claims description 17
- VSWICNJIUPRZIK-UHFFFAOYSA-N 2-piperideine Chemical compound C1CNC=CC1 VSWICNJIUPRZIK-UHFFFAOYSA-N 0.000 claims description 16
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 claims description 16
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 claims description 16
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical class C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 claims description 16
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 16
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 16
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 16
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 16
- AHHWIHXENZJRFG-UHFFFAOYSA-N oxetane Chemical compound C1COC1 AHHWIHXENZJRFG-UHFFFAOYSA-N 0.000 claims description 16
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 claims description 16
- SHQSVMDWKBRBGB-UHFFFAOYSA-N cyclobutanone Chemical compound O=C1CCC1 SHQSVMDWKBRBGB-UHFFFAOYSA-N 0.000 claims description 15
- 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 claims description 15
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 claims description 15
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 claims description 15
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 15
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 claims description 15
- 239000002904 solvent Substances 0.000 claims description 15
- BBVIDBNAYOIXOE-UHFFFAOYSA-N 1,2,4-oxadiazole Chemical compound C=1N=CON=1 BBVIDBNAYOIXOE-UHFFFAOYSA-N 0.000 claims description 14
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 claims description 14
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 claims description 14
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims description 14
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 14
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims description 14
- QDMRCCGQLCIMLG-UHFFFAOYSA-N cyclobutane-1,2-dione Chemical compound O=C1CCC1=O QDMRCCGQLCIMLG-UHFFFAOYSA-N 0.000 claims description 14
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 claims description 14
- 150000003536 tetrazoles Chemical class 0.000 claims description 14
- 229930192474 thiophene Natural products 0.000 claims description 14
- 150000003852 triazoles Chemical class 0.000 claims description 14
- JKFAIQOWCVVSKC-UHFFFAOYSA-N furazan Chemical compound C=1C=NON=1 JKFAIQOWCVVSKC-UHFFFAOYSA-N 0.000 claims description 13
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 claims description 13
- FKASFBLJDCHBNZ-UHFFFAOYSA-N 1,3,4-oxadiazole Chemical compound C1=NN=CO1 FKASFBLJDCHBNZ-UHFFFAOYSA-N 0.000 claims description 12
- XUWHAWMETYGRKB-UHFFFAOYSA-N piperidin-2-one Chemical compound O=C1CCCCN1 XUWHAWMETYGRKB-UHFFFAOYSA-N 0.000 claims description 12
- VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 claims description 12
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 11
- MUGSKSNNEORSJG-UHFFFAOYSA-N 3174-74-1 Chemical compound C1CC=CCO1 MUGSKSNNEORSJG-UHFFFAOYSA-N 0.000 claims description 11
- HJSLFCCWAKVHIW-UHFFFAOYSA-N cyclohexane-1,3-dione Chemical compound O=C1CCCC(=O)C1 HJSLFCCWAKVHIW-UHFFFAOYSA-N 0.000 claims description 11
- 125000006579 5 or 6-membered monocyclic heterocycloalkyl group Chemical group 0.000 claims description 10
- BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical compound C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 claims description 10
- 125000006582 (C5-C6) heterocycloalkyl group Chemical group 0.000 claims description 9
- JKTCBAGSMQIFNL-UHFFFAOYSA-N 2,3-dihydrofuran Chemical compound C1CC=CO1 JKTCBAGSMQIFNL-UHFFFAOYSA-N 0.000 claims description 9
- JVQIKJMSUIMUDI-UHFFFAOYSA-N 3-pyrroline Chemical compound C1NCC=C1 JVQIKJMSUIMUDI-UHFFFAOYSA-N 0.000 claims description 9
- WYNCHZVNFNFDNH-UHFFFAOYSA-N Oxazolidine Chemical compound C1COCN1 WYNCHZVNFNFDNH-UHFFFAOYSA-N 0.000 claims description 9
- DKYBVKMIZODYKL-UHFFFAOYSA-N 1,3-diazinane Chemical compound C1CNCNC1 DKYBVKMIZODYKL-UHFFFAOYSA-N 0.000 claims description 8
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 claims description 8
- VPVXHAANQNHFSF-UHFFFAOYSA-N 1,4-dioxan-2-one Chemical compound O=C1COCCO1 VPVXHAANQNHFSF-UHFFFAOYSA-N 0.000 claims description 8
- QBDAFARLDLCWAT-UHFFFAOYSA-N 2,3-dihydropyran-6-one Chemical compound O=C1OCCC=C1 QBDAFARLDLCWAT-UHFFFAOYSA-N 0.000 claims description 8
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical compound O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 claims description 8
- YEJRWHAVMIAJKC-UHFFFAOYSA-N 4-Butyrolactone Chemical compound O=C1CCCO1 YEJRWHAVMIAJKC-UHFFFAOYSA-N 0.000 claims description 8
- WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 claims description 8
- YAMHXTCMCPHKLN-UHFFFAOYSA-N imidazolidin-2-one Chemical compound O=C1NCCN1 YAMHXTCMCPHKLN-UHFFFAOYSA-N 0.000 claims description 8
- VSEAAEQOQBMPQF-UHFFFAOYSA-N morpholin-3-one Chemical compound O=C1COCCN1 VSEAAEQOQBMPQF-UHFFFAOYSA-N 0.000 claims description 8
- IWELDVXSEVIIGI-UHFFFAOYSA-N piperazin-2-one Chemical compound O=C1CNCCN1 IWELDVXSEVIIGI-UHFFFAOYSA-N 0.000 claims description 8
- JQLQRTIYJFIXIE-UHFFFAOYSA-N 1,1-dioxo-1,4-thiazinan-3-one Chemical compound O=C1CS(=O)(=O)CCN1 JQLQRTIYJFIXIE-UHFFFAOYSA-N 0.000 claims description 7
- NQPJDJVGBDHCAD-UHFFFAOYSA-N 1,3-diazinan-2-one Chemical compound OC1=NCCCN1 NQPJDJVGBDHCAD-UHFFFAOYSA-N 0.000 claims description 7
- FTAHXMZRJCZXDL-UHFFFAOYSA-N 3-piperideine Chemical compound C1CC=CCN1 FTAHXMZRJCZXDL-UHFFFAOYSA-N 0.000 claims description 7
- OZJPLYNZGCXSJM-UHFFFAOYSA-N 5-valerolactone Chemical compound O=C1CCCCO1 OZJPLYNZGCXSJM-UHFFFAOYSA-N 0.000 claims description 7
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 7
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 7
- LOGSONSNCYTHPS-UHFFFAOYSA-N cyclopentane-1,3-dione Chemical compound O=C1CCC(=O)C1 LOGSONSNCYTHPS-UHFFFAOYSA-N 0.000 claims description 7
- KNCYXPMJDCCGSJ-UHFFFAOYSA-N piperidine-2,6-dione Chemical compound O=C1CCCC(=O)N1 KNCYXPMJDCCGSJ-UHFFFAOYSA-N 0.000 claims description 7
- RINCXYDBBGOEEQ-UHFFFAOYSA-N succinic anhydride Chemical compound O=C1CCC(=O)O1 RINCXYDBBGOEEQ-UHFFFAOYSA-N 0.000 claims description 7
- KGWNRZLPXLBMPS-UHFFFAOYSA-N 2h-1,3-oxazine Chemical compound C1OC=CC=N1 KGWNRZLPXLBMPS-UHFFFAOYSA-N 0.000 claims description 6
- 208000011231 Crohn disease Diseases 0.000 claims description 6
- KMTRUDSVKNLOMY-UHFFFAOYSA-N Ethylene carbonate Chemical compound O=C1OCCO1 KMTRUDSVKNLOMY-UHFFFAOYSA-N 0.000 claims description 6
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 6
- 201000004681 Psoriasis Diseases 0.000 claims description 6
- 208000006011 Stroke Diseases 0.000 claims description 6
- MNFORVFSTILPAW-UHFFFAOYSA-N azetidin-2-one Chemical compound O=C1CCN1 MNFORVFSTILPAW-UHFFFAOYSA-N 0.000 claims description 6
- 208000035475 disorder Diseases 0.000 claims description 6
- ZQHJAAMMKABEBS-UHFFFAOYSA-N morpholin-2-one Chemical compound O=C1CNCCO1 ZQHJAAMMKABEBS-UHFFFAOYSA-N 0.000 claims description 6
- 125000005915 C6-C14 aryl group Chemical group 0.000 claims description 5
- VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 claims description 5
- 125000001624 naphthyl group Chemical group 0.000 claims description 5
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 5
- 229940124639 Selective inhibitor Drugs 0.000 claims description 3
- 230000005764 inhibitory process Effects 0.000 claims description 3
- LQPOOAJESJYDLS-UHFFFAOYSA-N 1,3-oxazinane Chemical compound C1CNCOC1 LQPOOAJESJYDLS-UHFFFAOYSA-N 0.000 claims description 2
- 206010019280 Heart failures Diseases 0.000 claims description 2
- 150000002576 ketones Chemical class 0.000 claims description 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims description 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 2
- 125000003554 tetrahydropyrrolyl group Chemical group 0.000 claims description 2
- PCIDEZQIKCRKQI-UHFFFAOYSA-N N1C=CC=C1.O1C=NN=C1 Chemical compound N1C=CC=C1.O1C=NN=C1 PCIDEZQIKCRKQI-UHFFFAOYSA-N 0.000 claims 1
- ZTRPYTHOEREHEN-UHFFFAOYSA-N piperazine pyridine Chemical compound N1CCNCC1.N1=CC=CC=C1.N1=CC=CC=C1 ZTRPYTHOEREHEN-UHFFFAOYSA-N 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 abstract description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 372
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 187
- 238000006243 chemical reaction Methods 0.000 description 182
- 239000000243 solution Substances 0.000 description 136
- 239000008186 active pharmaceutical agent Substances 0.000 description 126
- 238000003786 synthesis reaction Methods 0.000 description 113
- 230000015572 biosynthetic process Effects 0.000 description 110
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 106
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 89
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 77
- GPAYUJZHTULNBE-UHFFFAOYSA-N diphenylphosphine Chemical compound C=1C=CC=CC=1PC1=CC=CC=C1 GPAYUJZHTULNBE-UHFFFAOYSA-N 0.000 description 57
- KTWOOEGAPBSYNW-UHFFFAOYSA-N ferrocene Chemical compound [Fe+2].C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 KTWOOEGAPBSYNW-UHFFFAOYSA-N 0.000 description 57
- FNKVKNLXONZZJS-UHFFFAOYSA-N methyl 5-bromo-2-ethenylpyridine-3-carboxylate Chemical compound COC(=O)C1=CC(Br)=CN=C1C=C FNKVKNLXONZZJS-UHFFFAOYSA-N 0.000 description 55
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 54
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 51
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 48
- 239000012043 crude product Substances 0.000 description 48
- 239000000741 silica gel Substances 0.000 description 48
- 229910002027 silica gel Inorganic materials 0.000 description 48
- 125000006413 ring segment Chemical group 0.000 description 47
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical class CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 46
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 42
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 42
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 42
- 239000000706 filtrate Substances 0.000 description 41
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 38
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 35
- 238000003818 flash chromatography Methods 0.000 description 34
- 239000012074 organic phase Substances 0.000 description 33
- 239000012065 filter cake Substances 0.000 description 31
- 125000004526 pyridazin-2-yl group Chemical group N1N(C=CC=C1)* 0.000 description 30
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 28
- 238000004128 high performance liquid chromatography Methods 0.000 description 27
- 239000007787 solid Substances 0.000 description 27
- 125000005842 heteroatom Chemical group 0.000 description 26
- 239000000203 mixture Substances 0.000 description 26
- 239000012044 organic layer Substances 0.000 description 26
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 25
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 24
- 229910052799 carbon Inorganic materials 0.000 description 24
- 125000003367 polycyclic group Chemical group 0.000 description 24
- 238000005481 NMR spectroscopy Methods 0.000 description 22
- IVDFJHOHABJVEH-UHFFFAOYSA-N pinacol Chemical compound CC(C)(O)C(C)(C)O IVDFJHOHABJVEH-UHFFFAOYSA-N 0.000 description 22
- 229910000029 sodium carbonate Inorganic materials 0.000 description 21
- QVOJTBNUMGJQSX-UHFFFAOYSA-N n-(6-chloroimidazo[1,2-b]pyridazin-2-yl)acetamide Chemical compound N1=C(Cl)C=CC2=NC(NC(=O)C)=CN21 QVOJTBNUMGJQSX-UHFFFAOYSA-N 0.000 description 20
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 18
- 101710138589 Receptor-interacting serine/threonine-protein kinase 1 Proteins 0.000 description 18
- 239000011541 reaction mixture Substances 0.000 description 18
- 238000000034 method Methods 0.000 description 16
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 15
- MOMQDEDQGJAKII-UHFFFAOYSA-N methyl 5-bromo-2-chloropyridine-3-carboxylate Chemical compound COC(=O)C1=CC(Br)=CN=C1Cl MOMQDEDQGJAKII-UHFFFAOYSA-N 0.000 description 15
- 235000011056 potassium acetate Nutrition 0.000 description 14
- 238000004587 chromatography analysis Methods 0.000 description 13
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 12
- 229910020008 S(O) Inorganic materials 0.000 description 12
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 12
- 239000001301 oxygen Substances 0.000 description 12
- PUGSMBGTNDCQBX-UHFFFAOYSA-N 3,5-difluoro-2-(oxan-4-yloxy)benzonitrile Chemical compound FC=1C(=C(C#N)C=C(C=1)F)OC1CCOCC1 PUGSMBGTNDCQBX-UHFFFAOYSA-N 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- PSVDOJBKOZMMID-UHFFFAOYSA-N C1=C(F)C=C(C(=C1CN)OC1CCOCC1)F Chemical compound C1=C(F)C=C(C(=C1CN)OC1CCOCC1)F PSVDOJBKOZMMID-UHFFFAOYSA-N 0.000 description 10
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 10
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 10
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical class N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 10
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 10
- 239000012346 acetyl chloride Substances 0.000 description 10
- 150000002460 imidazoles Chemical class 0.000 description 10
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 10
- BMIBJCFFZPYJHF-UHFFFAOYSA-N 2-methoxy-5-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine Chemical compound COC1=NC=C(C)C=C1B1OC(C)(C)C(C)(C)O1 BMIBJCFFZPYJHF-UHFFFAOYSA-N 0.000 description 9
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- LERWXEBLMJFDDI-UHFFFAOYSA-N C1CN(C(=O)C2=C1N=CC(=C2)Br)CC3=C(C=CC(=C3)OC(F)(F)F)F Chemical compound C1CN(C(=O)C2=C1N=CC(=C2)Br)CC3=C(C=CC(=C3)OC(F)(F)F)F LERWXEBLMJFDDI-UHFFFAOYSA-N 0.000 description 9
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 9
- MBNLPGBRZXRZOM-UHFFFAOYSA-N [2-fluoro-5-(trifluoromethoxy)phenyl]methanamine Chemical compound NCC1=CC(OC(F)(F)F)=CC=C1F MBNLPGBRZXRZOM-UHFFFAOYSA-N 0.000 description 9
- 125000002188 cycloheptatrienyl group Chemical group C1(=CC=CC=CC1)* 0.000 description 9
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 9
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 9
- VBXDEEVJTYBRJJ-UHFFFAOYSA-N diboronic acid Chemical compound OBOBO VBXDEEVJTYBRJJ-UHFFFAOYSA-N 0.000 description 9
- 239000005457 ice water Substances 0.000 description 9
- 238000010992 reflux Methods 0.000 description 9
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 8
- GIVCDUMLVJOGDW-UHFFFAOYSA-N N1=C2C(=CC(=C1)Br)C(=O)N(CC2)CC1=CC=CC=C1OC(F)(F)F Chemical compound N1=C2C(=CC(=C1)Br)C(=O)N(CC2)CC1=CC=CC=C1OC(F)(F)F GIVCDUMLVJOGDW-UHFFFAOYSA-N 0.000 description 8
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 8
- 239000012071 phase Substances 0.000 description 8
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical class C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 description 7
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 7
- 206010028851 Necrosis Diseases 0.000 description 7
- 239000002585 base Substances 0.000 description 7
- 150000003997 cyclic ketones Chemical group 0.000 description 7
- 230000000670 limiting effect Effects 0.000 description 7
- 230000017074 necrotic cell death Effects 0.000 description 7
- 229910052717 sulfur Inorganic materials 0.000 description 7
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 6
- MMPKVFQMDMBXSG-UHFFFAOYSA-N 2,3,5-trifluorobenzonitrile Chemical compound FC1=CC(F)=C(F)C(C#N)=C1 MMPKVFQMDMBXSG-UHFFFAOYSA-N 0.000 description 6
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- QOYDCRJETQCWJU-UHFFFAOYSA-N N-(5,6,7,8-tetrahydro-[1,2,4]triazolo[1,5-a]pyrazin-2-yl)acetamide Chemical compound N=1C(=NN2C=1CNCC2)NC(C)=O QOYDCRJETQCWJU-UHFFFAOYSA-N 0.000 description 6
- YYIDGSQESKOKPA-UHFFFAOYSA-N N-([1,2,4]triazolo[1,5-a]pyrazin-2-yl)acetamide Chemical compound C=1N=CC=2N(C=1)N=C(N=2)NC(=O)C YYIDGSQESKOKPA-UHFFFAOYSA-N 0.000 description 6
- 206010063837 Reperfusion injury Diseases 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- NDQKGYXNMLOECO-UHFFFAOYSA-N acetic acid;potassium Chemical compound [K].CC(O)=O NDQKGYXNMLOECO-UHFFFAOYSA-N 0.000 description 6
- 150000001335 aliphatic alkanes Chemical group 0.000 description 6
- 230000006907 apoptotic process Effects 0.000 description 6
- 150000001721 carbon Chemical group 0.000 description 6
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 6
- XSCHRSMBECNVNS-UHFFFAOYSA-N quinoxaline Chemical compound N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 6
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 5
- YWTDPFRLJYZIQN-UHFFFAOYSA-N CC(NC1=NN(CCN(C2)C3=CC(C(N(CC(C=C(C=C4)OC(F)(F)F)=C4F)CC4)=O)=C4N=C3)C2=N1)=O Chemical compound CC(NC1=NN(CCN(C2)C3=CC(C(N(CC(C=C(C=C4)OC(F)(F)F)=C4F)CC4)=O)=C4N=C3)C2=N1)=O YWTDPFRLJYZIQN-UHFFFAOYSA-N 0.000 description 5
- 101710156256 Myosin phosphatase Rho-interacting protein Proteins 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 102100033729 Receptor-interacting serine/threonine-protein kinase 3 Human genes 0.000 description 5
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 5
- 239000012141 concentrate Substances 0.000 description 5
- 235000008504 concentrate Nutrition 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- 125000000623 heterocyclic group Chemical group 0.000 description 5
- 235000011167 hydrochloric acid Nutrition 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 238000010791 quenching Methods 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- CSNIZNHTOVFARY-UHFFFAOYSA-N 1,2-benzothiazole Chemical compound C1=CC=C2C=NSC2=C1 CSNIZNHTOVFARY-UHFFFAOYSA-N 0.000 description 4
- KTZQTRPPVKQPFO-UHFFFAOYSA-N 1,2-benzoxazole Chemical compound C1=CC=C2C=NOC2=C1 KTZQTRPPVKQPFO-UHFFFAOYSA-N 0.000 description 4
- FLBAYUMRQUHISI-UHFFFAOYSA-N 1,8-naphthyridine Chemical compound N1=CC=CC2=CC=CN=C21 FLBAYUMRQUHISI-UHFFFAOYSA-N 0.000 description 4
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 4
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 4
- VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical compound C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 description 4
- WIVLIANZPLNBBY-UHFFFAOYSA-N C1=C(C=CC(=C1CN1C(=O)C2=C(N=CC(=C2)Br)CC1)CN1CCOCC1)F Chemical compound C1=C(C=CC(=C1CN1C(=O)C2=C(N=CC(=C2)Br)CC1)CN1CCOCC1)F WIVLIANZPLNBBY-UHFFFAOYSA-N 0.000 description 4
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- IEIPXRLPMIPWIF-UHFFFAOYSA-N N1=C2C(=CC(=C1)B1OC(C(C)(O1)C)(C)C)C(=O)N(CC2)CC1=C(F)C=CC(OC(F)(F)F)=C1 Chemical compound N1=C2C(=CC(=C1)B1OC(C(C)(O1)C)(C)C)C(=O)N(CC2)CC1=C(F)C=CC(OC(F)(F)F)=C1 IEIPXRLPMIPWIF-UHFFFAOYSA-N 0.000 description 4
- 108091000080 Phosphotransferase Proteins 0.000 description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 description 4
- QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical compound C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 description 4
- MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical compound C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 230000030833 cell death Effects 0.000 description 4
- WCZVZNOTHYJIEI-UHFFFAOYSA-N cinnoline Chemical compound N1=NC=CC2=CC=CC=C21 WCZVZNOTHYJIEI-UHFFFAOYSA-N 0.000 description 4
- 239000000470 constituent Substances 0.000 description 4
- 125000004122 cyclic group Chemical group 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 4
- XONPDZSGENTBNJ-UHFFFAOYSA-N molecular hydrogen;sodium Chemical compound [Na].[H][H] XONPDZSGENTBNJ-UHFFFAOYSA-N 0.000 description 4
- SSYOFQPMJUGXDU-UHFFFAOYSA-N n-(6-chloroimidazo[1,2-b]pyridazin-2-yl)cyclopropanecarboxamide Chemical compound C=1N2N=C(Cl)C=CC2=NC=1NC(=O)C1CC1 SSYOFQPMJUGXDU-UHFFFAOYSA-N 0.000 description 4
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 4
- LMYJGUNNJIDROI-UHFFFAOYSA-N oxan-4-ol Chemical compound OC1CCOCC1 LMYJGUNNJIDROI-UHFFFAOYSA-N 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 102000020233 phosphotransferase Human genes 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- BWESROVQGZSBRX-UHFFFAOYSA-N pyrido[3,2-d]pyrimidine Chemical compound C1=NC=NC2=CC=CN=C21 BWESROVQGZSBRX-UHFFFAOYSA-N 0.000 description 4
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 4
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 4
- 239000011593 sulfur Substances 0.000 description 4
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 4
- IHHVRUXJQNBVNI-UHFFFAOYSA-N (2-acetamidoimidazo[1,2-b]pyridazin-6-yl)boronic acid Chemical compound CC(=O)NC1=CN2N=C(C=CC2=N1)B(O)O IHHVRUXJQNBVNI-UHFFFAOYSA-N 0.000 description 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 3
- OEHIYNMMAZCNCE-UHFFFAOYSA-N 6-bromo-1-methylbenzimidazol-2-amine Chemical compound C1=C(Br)C=C2N(C)C(N)=NC2=C1 OEHIYNMMAZCNCE-UHFFFAOYSA-N 0.000 description 3
- HHPQJKRWXZKCQC-UHFFFAOYSA-N 7-bromo-5-iodo-N,N-bis[(4-methoxyphenyl)methyl]pyrrolo[2,1-f][1,2,4]triazin-4-amine Chemical compound COC1=CC=C(CN(CC2=CC=C(OC)C=C2)C2=NC=NN3C(Br)=CC(I)=C23)C=C1 HHPQJKRWXZKCQC-UHFFFAOYSA-N 0.000 description 3
- QAVJLZOTROAVOE-UHFFFAOYSA-N 7-bromo-N,N-bis[(4-methoxyphenyl)methyl]pyrrolo[2,1-f][1,2,4]triazin-4-amine Chemical compound COC1=CC=C(CN(CC2=CC=C(OC)C=C2)C2=NC=NN3C(Br)=CC=C23)C=C1 QAVJLZOTROAVOE-UHFFFAOYSA-N 0.000 description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- 201000006474 Brain Ischemia Diseases 0.000 description 3
- LCPIHWJOWAODFP-UHFFFAOYSA-N C1=C(C=C(C(=C1CN1C(=O)C2=C(N=CC(C3=CC=NC=C3)=C2)CC1)OC1CCOCC1)F)F Chemical compound C1=C(C=C(C(=C1CN1C(=O)C2=C(N=CC(C3=CC=NC=C3)=C2)CC1)OC1CCOCC1)F)F LCPIHWJOWAODFP-UHFFFAOYSA-N 0.000 description 3
- VDKJXQIIOGRTAI-UHFFFAOYSA-N C1CC1OC2=C(C=C(C=C2F)F)CN3CCC4=C(C3=O)C=C(C=N4)Br Chemical compound C1CC1OC2=C(C=C(C=C2F)F)CN3CCC4=C(C3=O)C=C(C=N4)Br VDKJXQIIOGRTAI-UHFFFAOYSA-N 0.000 description 3
- KSOSLVBXJIEOOD-UHFFFAOYSA-N CC(NC(N=C1C=C2)=CN1N=C2C1=CC(C(N(CC(C=C(C=C2)F)=C2C2=CN(C)N=C2)CC2)=O)=C2N=C1)=O Chemical compound CC(NC(N=C1C=C2)=CN1N=C2C1=CC(C(N(CC(C=C(C=C2)F)=C2C2=CN(C)N=C2)CC2)=O)=C2N=C1)=O KSOSLVBXJIEOOD-UHFFFAOYSA-N 0.000 description 3
- BBKJKBCRIAKVRY-UHFFFAOYSA-N CC(NC(N=C1C=C2)=CN1N=C2C1=CC(C(N(CC(C=C(C=C2)F)=C2OC2CCOCC2)CC2)=O)=C2N=C1)=O Chemical compound CC(NC(N=C1C=C2)=CN1N=C2C1=CC(C(N(CC(C=C(C=C2)F)=C2OC2CCOCC2)CC2)=O)=C2N=C1)=O BBKJKBCRIAKVRY-UHFFFAOYSA-N 0.000 description 3
- ZYUJZSRLZZWNFP-UHFFFAOYSA-N CC(NC(N=C1C=C2)=CN1N=C2C1=CC(C(N(CC(C=C(C=C2F)F)=C2OC2CCOCC2)CC2)=O)=C2N=C1)=O Chemical compound CC(NC(N=C1C=C2)=CN1N=C2C1=CC(C(N(CC(C=C(C=C2F)F)=C2OC2CCOCC2)CC2)=O)=C2N=C1)=O ZYUJZSRLZZWNFP-UHFFFAOYSA-N 0.000 description 3
- HONMQTOKGGGMLO-UHFFFAOYSA-N CC(NC(N=C1C=C2)=CN1N=C2C1=CC(C(N(CC(C=C(C=C2F)F)=C2OC2COCC2)CC2)=O)=C2N=C1)=O Chemical compound CC(NC(N=C1C=C2)=CN1N=C2C1=CC(C(N(CC(C=C(C=C2F)F)=C2OC2COCC2)CC2)=O)=C2N=C1)=O HONMQTOKGGGMLO-UHFFFAOYSA-N 0.000 description 3
- VZXXXHXFENNZLD-UHFFFAOYSA-N CC(NC(N=C1C=C2)=CN1N=C2C1=CC(C(N(CC2=CC(OC(F)(F)F)=CC=C2)CC2)=O)=C2N=C1)=O Chemical compound CC(NC(N=C1C=C2)=CN1N=C2C1=CC(C(N(CC2=CC(OC(F)(F)F)=CC=C2)CC2)=O)=C2N=C1)=O VZXXXHXFENNZLD-UHFFFAOYSA-N 0.000 description 3
- PMMQXQVAEYRWBY-UHFFFAOYSA-N CC1=NN(C=CC(C2=CC(C(N(CC(C=C(C=C3)OC(F)(F)F)=C3F)CC3)=O)=C3N=C2)=C2)C2=N1 Chemical compound CC1=NN(C=CC(C2=CC(C(N(CC(C=C(C=C3)OC(F)(F)F)=C3F)CC3)=O)=C3N=C2)=C2)C2=N1 PMMQXQVAEYRWBY-UHFFFAOYSA-N 0.000 description 3
- QFQBBNLDFBUUBX-UHFFFAOYSA-N CNC1=C(C(=CC(=C1)F)F)OC2CC2 Chemical compound CNC1=C(C(=CC(=C1)F)F)OC2CC2 QFQBBNLDFBUUBX-UHFFFAOYSA-N 0.000 description 3
- 108090000538 Caspase-8 Proteins 0.000 description 3
- 102000004091 Caspase-8 Human genes 0.000 description 3
- 206010008120 Cerebral ischaemia Diseases 0.000 description 3
- 102000010170 Death domains Human genes 0.000 description 3
- 108050001718 Death domains Proteins 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 3
- 101000850748 Homo sapiens Tumor necrosis factor receptor type 1-associated DEATH domain protein Proteins 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- FWBUFCVHLDIQNZ-UHFFFAOYSA-N N1=C2C(=CC(=C1)C1=CC=3N(C(=NC=3C=C1)N)C)C(=O)N(CC2)CC1=C(F)C=CC(=C1)OC(F)(F)F Chemical compound N1=C2C(=CC(=C1)C1=CC=3N(C(=NC=3C=C1)N)C)C(=O)N(CC2)CC1=C(F)C=CC(=C1)OC(F)(F)F FWBUFCVHLDIQNZ-UHFFFAOYSA-N 0.000 description 3
- CUOLXWSTOFJFLY-UHFFFAOYSA-N N1=C2C(=CC(=C1)C1=NN3C(=NC(NC(=O)C4CC4)=C3)C=C1)C(=O)N(CC2)CC1=CC=CC=C1OC(F)(F)F Chemical compound N1=C2C(=CC(=C1)C1=NN3C(=NC(NC(=O)C4CC4)=C3)C=C1)C(=O)N(CC2)CC1=CC=CC=C1OC(F)(F)F CUOLXWSTOFJFLY-UHFFFAOYSA-N 0.000 description 3
- YYKBKAXGVQXFDX-UHFFFAOYSA-N NC1=NC=NN2C1=C(C(F)(F)F)C=C2C1=CC(C(N(CC(C=C(C=C2)OC(F)(F)F)=C2F)CC2)=O)=C2N=C1 Chemical compound NC1=NC=NN2C1=C(C(F)(F)F)C=C2C1=CC(C(N(CC(C=C(C=C2)OC(F)(F)F)=C2F)CC2)=O)=C2N=C1 YYKBKAXGVQXFDX-UHFFFAOYSA-N 0.000 description 3
- BOYZXDSFAAFHSB-UHFFFAOYSA-N O=C1N(CC(C=C(C=C2F)F)=C2OC2CCOCC2)CCC(N=C2)=C1C=C2C1=NC=CC=C1 Chemical compound O=C1N(CC(C=C(C=C2F)F)=C2OC2CCOCC2)CCC(N=C2)=C1C=C2C1=NC=CC=C1 BOYZXDSFAAFHSB-UHFFFAOYSA-N 0.000 description 3
- CFQVGILARUXDNX-UHFFFAOYSA-N O=C1N(CC2=CC(OC(F)(F)F)=CC=C2)CCC(N=C2)=C1C=C2Br Chemical compound O=C1N(CC2=CC(OC(F)(F)F)=CC=C2)CCC(N=C2)=C1C=C2Br CFQVGILARUXDNX-UHFFFAOYSA-N 0.000 description 3
- 206010040070 Septic Shock Diseases 0.000 description 3
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 description 3
- 102100033081 Tumor necrosis factor receptor type 1-associated DEATH domain protein Human genes 0.000 description 3
- QUGKADBXWCMHNB-UHFFFAOYSA-N [5-fluoro-2-(morpholin-4-ylmethyl)phenyl]methanamine Chemical compound NCC1=CC(F)=CC=C1CN1CCOCC1 QUGKADBXWCMHNB-UHFFFAOYSA-N 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 125000001931 aliphatic group Chemical group 0.000 description 3
- 125000003342 alkenyl group Chemical group 0.000 description 3
- 230000033115 angiogenesis Effects 0.000 description 3
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 3
- 206010008118 cerebral infarction Diseases 0.000 description 3
- 239000012295 chemical reaction liquid Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000011737 fluorine Substances 0.000 description 3
- 229910052731 fluorine Inorganic materials 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 230000004770 neurodegeneration Effects 0.000 description 3
- 208000015122 neurodegenerative disease Diseases 0.000 description 3
- 229910052763 palladium Inorganic materials 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 150000003222 pyridines Chemical class 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000000967 suction filtration Methods 0.000 description 3
- 125000004434 sulfur atom Chemical group 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 2
- 125000006584 (C3-C10) heterocycloalkyl group Chemical group 0.000 description 2
- 125000006651 (C3-C20) cycloalkyl group Chemical group 0.000 description 2
- 125000005918 1,2-dimethylbutyl group Chemical group 0.000 description 2
- VMLKTERJLVWEJJ-UHFFFAOYSA-N 1,5-naphthyridine Chemical compound C1=CC=NC2=CC=CN=C21 VMLKTERJLVWEJJ-UHFFFAOYSA-N 0.000 description 2
- VSOSXKMEQPYESP-UHFFFAOYSA-N 1,6-naphthyridine Chemical compound C1=CN=CC2=CC=CN=C21 VSOSXKMEQPYESP-UHFFFAOYSA-N 0.000 description 2
- MXBVNILGVJVVMH-UHFFFAOYSA-N 1,7-naphthyridine Chemical compound C1=NC=CC2=CC=CN=C21 MXBVNILGVJVVMH-UHFFFAOYSA-N 0.000 description 2
- UJBQLUACSHFDBU-UHFFFAOYSA-N 1-[1-(4-fluorophenyl)ethyl]-4-nitropyrazole Chemical compound CC(N1C=C(C=N1)[N+]([O-])=O)C1=CC=C(F)C=C1 UJBQLUACSHFDBU-UHFFFAOYSA-N 0.000 description 2
- YXPPMGABLZFJGY-UHFFFAOYSA-N 1-[1-(4-fluorophenyl)ethyl]pyrazol-4-amine Chemical compound CC(N1C=C(N)C=N1)C1=CC=C(F)C=C1 YXPPMGABLZFJGY-UHFFFAOYSA-N 0.000 description 2
- XDQINUYPIQISSS-UHFFFAOYSA-N 1-[2-(trifluoromethoxy)phenyl]ethanamine Chemical compound CC(N)C1=CC=CC=C1OC(F)(F)F XDQINUYPIQISSS-UHFFFAOYSA-N 0.000 description 2
- MKBAMMMBEHOLHI-UHFFFAOYSA-N 1H-pyrrole 1H-1,2,4-triazole Chemical compound N1N=CN=C1.N1C=CC=C1 MKBAMMMBEHOLHI-UHFFFAOYSA-N 0.000 description 2
- DNCYBUMDUBHIJZ-UHFFFAOYSA-N 1h-pyrimidin-6-one Chemical compound O=C1C=CN=CN1 DNCYBUMDUBHIJZ-UHFFFAOYSA-N 0.000 description 2
- 125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 2
- 125000005916 2-methylpentyl group Chemical group 0.000 description 2
- UOFDOEHLKSGKQD-UHFFFAOYSA-N 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-6-[[2-(trifluoromethoxy)phenyl]methyl]-7,8-dihydro-1,6-naphthyridin-5-one Chemical compound N1=C2C(=CC(=C1)B1OC(C(C)(O1)C)(C)C)C(=O)N(CC2)CC1=CC=CC=C1OC(F)(F)F UOFDOEHLKSGKQD-UHFFFAOYSA-N 0.000 description 2
- 125000003542 3-methylbutan-2-yl group Chemical group [H]C([H])([H])C([H])(*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 125000005917 3-methylpentyl group Chemical group 0.000 description 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 2
- IHXNIOYEXQWUNI-UHFFFAOYSA-N 4,5-dihydro-1h-pyrimidin-6-one Chemical compound O=C1CCN=CN1 IHXNIOYEXQWUNI-UHFFFAOYSA-N 0.000 description 2
- OXRRHYRRQWIHIV-UHFFFAOYSA-N 5,6-dihdyro-1H-pyridin-2-one Natural products O=C1NCCC=C1 OXRRHYRRQWIHIV-UHFFFAOYSA-N 0.000 description 2
- TXUWMXQFNYDOEZ-UHFFFAOYSA-N 5-(1H-indol-3-ylmethyl)-3-methyl-2-sulfanylidene-4-imidazolidinone Chemical compound O=C1N(C)C(=S)NC1CC1=CNC2=CC=CC=C12 TXUWMXQFNYDOEZ-UHFFFAOYSA-N 0.000 description 2
- LZWPIPUIMILIPE-UHFFFAOYSA-N 5-fluoro-2-(oxan-4-yloxy)benzonitrile Chemical compound N#CC1=CC(F)=CC=C1OC1CCOCC1 LZWPIPUIMILIPE-UHFFFAOYSA-N 0.000 description 2
- GGAMPBLWOQFRCA-UHFFFAOYSA-N 7-bromo-5-(trifluoromethyl)pyrrolo[2,1-f][1,2,4]triazin-4-amine Chemical compound NC1=NC=NN2C(Br)=CC(=C12)C(F)(F)F GGAMPBLWOQFRCA-UHFFFAOYSA-N 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 2
- 208000004429 Bacillary Dysentery Diseases 0.000 description 2
- 208000023328 Basedow disease Diseases 0.000 description 2
- 208000020084 Bone disease Diseases 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- KAKZBPTYRLMSJV-UHFFFAOYSA-N Butadiene Chemical compound C=CC=C KAKZBPTYRLMSJV-UHFFFAOYSA-N 0.000 description 2
- QNYXQDLQFFHGEW-UHFFFAOYSA-N C1(=CC(F)=CC(=C1OC1CCOCC1)F)CN1C(=O)C2=C(N=CC(=C2)C2=CC3=NC=NN3C=C2)CC1 Chemical compound C1(=CC(F)=CC(=C1OC1CCOCC1)F)CN1C(=O)C2=C(N=CC(=C2)C2=CC3=NC=NN3C=C2)CC1 QNYXQDLQFFHGEW-UHFFFAOYSA-N 0.000 description 2
- YRCNVQHHEQLHJY-UHFFFAOYSA-N C1=C(C=CC(=C1C#N)C1=CN(N=C1)C)F Chemical compound C1=C(C=CC(=C1C#N)C1=CN(N=C1)C)F YRCNVQHHEQLHJY-UHFFFAOYSA-N 0.000 description 2
- KPODNIKSJUIHAY-UHFFFAOYSA-N C1CC1OC2=C(C=C(C=C2F)F)C#N Chemical compound C1CC1OC2=C(C=C(C=C2F)F)C#N KPODNIKSJUIHAY-UHFFFAOYSA-N 0.000 description 2
- OMFCAVBOPXTEON-UHFFFAOYSA-N CC(C1=CC=CC=C1OC(F)(F)F)N2CCC3=C(C2=O)C=C(C=N3)Br Chemical compound CC(C1=CC=CC=C1OC(F)(F)F)N2CCC3=C(C2=O)C=C(C=N3)Br OMFCAVBOPXTEON-UHFFFAOYSA-N 0.000 description 2
- RHMQYSUWGWPQEU-UHFFFAOYSA-N CC(NC(N=C1C=C2)=CN1N=C2C1=CC(C(N(CC(C=C(C=C2)F)=C2C2=NN(C)C=N2)CC2)=O)=C2N=C1)=O Chemical compound CC(NC(N=C1C=C2)=CN1N=C2C1=CC(C(N(CC(C=C(C=C2)F)=C2C2=NN(C)C=N2)CC2)=O)=C2N=C1)=O RHMQYSUWGWPQEU-UHFFFAOYSA-N 0.000 description 2
- IBALSCPMABCRLU-UHFFFAOYSA-N CC(NC(N=C1C=C2)=CN1N=C2C1=CC(C(N(CC(C=CC=C2)=C2OC(F)(F)F)CC2)=O)=C2N=C1)=O Chemical compound CC(NC(N=C1C=C2)=CN1N=C2C1=CC(C(N(CC(C=CC=C2)=C2OC(F)(F)F)CC2)=O)=C2N=C1)=O IBALSCPMABCRLU-UHFFFAOYSA-N 0.000 description 2
- 206010006895 Cachexia Diseases 0.000 description 2
- 241000282421 Canidae Species 0.000 description 2
- 102000011727 Caspases Human genes 0.000 description 2
- 108010076667 Caspases Proteins 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 2
- 206010048843 Cytomegalovirus chorioretinitis Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 2
- 102100026693 FAS-associated death domain protein Human genes 0.000 description 2
- XUAXPUVLCYENGP-UHFFFAOYSA-N FC(OC1=C(CN(CC2)CC3=C2N=CC(Br)=C3)C=CC=C1)(F)F Chemical compound FC(OC1=C(CN(CC2)CC3=C2N=CC(Br)=C3)C=CC=C1)(F)F XUAXPUVLCYENGP-UHFFFAOYSA-N 0.000 description 2
- RNCMAAYOPDRNPI-UHFFFAOYSA-N FC=1C=CC(=C(C#N)C1)CN1CCOCC1 Chemical compound FC=1C=CC(=C(C#N)C1)CN1CCOCC1 RNCMAAYOPDRNPI-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 201000005569 Gout Diseases 0.000 description 2
- 208000009329 Graft vs Host Disease Diseases 0.000 description 2
- 208000015023 Graves' disease Diseases 0.000 description 2
- 208000031886 HIV Infections Diseases 0.000 description 2
- 208000037357 HIV infectious disease Diseases 0.000 description 2
- 101000911074 Homo sapiens FAS-associated death domain protein Proteins 0.000 description 2
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 2
- 208000007766 Kaposi sarcoma Diseases 0.000 description 2
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 2
- 208000034578 Multiple myelomas Diseases 0.000 description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
- SOBLVOUXDXJKKB-UHFFFAOYSA-N N#CC(C=C(C=C1F)F)=C1OC1COCC1 Chemical compound N#CC(C=C(C=C1F)F)=C1OC1COCC1 SOBLVOUXDXJKKB-UHFFFAOYSA-N 0.000 description 2
- JLYCULQDBQCMOQ-UHFFFAOYSA-N N1=C2C(=CC(=C1)C1=CC=3NC(=NC=3C=C1)N)C(=O)N(CC2)CC1=C(F)C=CC(=C1)OC(F)(F)F Chemical compound N1=C2C(=CC(=C1)C1=CC=3NC(=NC=3C=C1)N)C(=O)N(CC2)CC1=C(F)C=CC(=C1)OC(F)(F)F JLYCULQDBQCMOQ-UHFFFAOYSA-N 0.000 description 2
- KLZVEWLGPLCKAU-UHFFFAOYSA-N N1=C2C(=CC(=C1)C1=NN3C(C=C1)=NC(N)=C3)C(=O)N(CC2)CC1=CC=CC=C1OC(F)(F)F Chemical compound N1=C2C(=CC(=C1)C1=NN3C(C=C1)=NC(N)=C3)C(=O)N(CC2)CC1=CC=CC=C1OC(F)(F)F KLZVEWLGPLCKAU-UHFFFAOYSA-N 0.000 description 2
- WWOIKWBPZDOMEL-UHFFFAOYSA-N N1N=CC=C1.S1N=NC=C1 Chemical compound N1N=CC=C1.S1N=NC=C1 WWOIKWBPZDOMEL-UHFFFAOYSA-N 0.000 description 2
- FYLBYNHFPBSXOD-UHFFFAOYSA-N NC1=NC(C=C(C=C2)C3=CC(C(N(CC(C=C(C=C4)OC(F)(F)F)=C4F)CC4)=O)=C4N=C3)=C2O1 Chemical compound NC1=NC(C=C(C=C2)C3=CC(C(N(CC(C=C(C=C4)OC(F)(F)F)=C4F)CC4)=O)=C4N=C3)=C2O1 FYLBYNHFPBSXOD-UHFFFAOYSA-N 0.000 description 2
- HCMQVPMNANPGBE-UHFFFAOYSA-N NC1=NC(C=CC(C2=CC(C(N(CC(C=C(C=C3)OC(F)(F)F)=C3F)CC3)=O)=C3N=C2)=C2)=C2O1 Chemical compound NC1=NC(C=CC(C2=CC(C(N(CC(C=C(C=C3)OC(F)(F)F)=C3F)CC3)=O)=C3N=C2)=C2)=C2O1 HCMQVPMNANPGBE-UHFFFAOYSA-N 0.000 description 2
- XANBDCUAPAVEBC-UHFFFAOYSA-N NC1=NN(CCN(C2)C3=CC(C(N(CC(C=C(C=C4)OC(F)(F)F)=C4F)CC4)=O)=C4N=C3)C2=N1 Chemical compound NC1=NN(CCN(C2)C3=CC(C(N(CC(C=C(C=C4)OC(F)(F)F)=C4F)CC4)=O)=C4N=C3)C2=N1 XANBDCUAPAVEBC-UHFFFAOYSA-N 0.000 description 2
- 206010029113 Neovascularisation Diseases 0.000 description 2
- SLRSAAHTDUPGIF-UHFFFAOYSA-N O=C1N(CC(C=C(C=C2)F)=C2OC2CCCC2)CCC(N=C2)=C1C=C2Br Chemical compound O=C1N(CC(C=C(C=C2)F)=C2OC2CCCC2)CCC(N=C2)=C1C=C2Br SLRSAAHTDUPGIF-UHFFFAOYSA-N 0.000 description 2
- DZRHLUPGUGMWAL-UHFFFAOYSA-N O=C1N(CC(C=C(C=C2F)F)=C2OC2COCC2)CCC(N=C2)=C1C=C2Br Chemical compound O=C1N(CC(C=C(C=C2F)F)=C2OC2COCC2)CCC(N=C2)=C1C=C2Br DZRHLUPGUGMWAL-UHFFFAOYSA-N 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 206010033645 Pancreatitis Diseases 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 201000011152 Pemphigus Diseases 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 2
- 206010040047 Sepsis Diseases 0.000 description 2
- 206010040550 Shigella infections Diseases 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- UUYSQAYUTMLLBO-UHFFFAOYSA-N [1,2,4]triazolo[1,5-a]pyrazin-2-amine Chemical compound C1=NC=CN2N=C(N)N=C21 UUYSQAYUTMLLBO-UHFFFAOYSA-N 0.000 description 2
- DACWQSNZECJJGG-UHFFFAOYSA-N [1,2,4]triazolo[1,5-a]pyridine Chemical class C1=CC=CN2N=CN=C21 DACWQSNZECJJGG-UHFFFAOYSA-N 0.000 description 2
- FYXMMFFZMQMXCQ-UHFFFAOYSA-N [2-(trifluoromethoxy)phenyl]methanamine Chemical compound NCC1=CC=CC=C1OC(F)(F)F FYXMMFFZMQMXCQ-UHFFFAOYSA-N 0.000 description 2
- OPWTWGHOBYQTNR-UHFFFAOYSA-N [5-fluoro-2-(1-methylpyrazol-4-yl)phenyl]methanamine Chemical compound C1=NN(C)C=C1C1=CC=C(F)C=C1CN OPWTWGHOBYQTNR-UHFFFAOYSA-N 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 150000001556 benzimidazoles Chemical class 0.000 description 2
- 239000012964 benzotriazole Substances 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 208000019664 bone resorption disease Diseases 0.000 description 2
- UWTDFICHZKXYAC-UHFFFAOYSA-N boron;oxolane Chemical compound [B].C1CCOC1 UWTDFICHZKXYAC-UHFFFAOYSA-N 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 208000001969 capillary hemangioma Diseases 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 229940126214 compound 3 Drugs 0.000 description 2
- 229940125898 compound 5 Drugs 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 125000004093 cyano group Chemical group *C#N 0.000 description 2
- 230000016396 cytokine production Effects 0.000 description 2
- 208000001763 cytomegalovirus retinitis Diseases 0.000 description 2
- 125000004431 deuterium atom Chemical group 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- AGCOMFFHXJMNLN-UHFFFAOYSA-N dichloromethane;dihydrochloride Chemical compound Cl.Cl.ClCCl AGCOMFFHXJMNLN-UHFFFAOYSA-N 0.000 description 2
- 125000004772 dichloromethyl group Chemical group [H]C(Cl)(Cl)* 0.000 description 2
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 2
- 125000006001 difluoroethyl group Chemical group 0.000 description 2
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 2
- 229910001882 dioxygen Inorganic materials 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 208000024908 graft versus host disease Diseases 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 2
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 2
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 2
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 238000011813 knockout mouse model Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 208000021039 metastatic melanoma Diseases 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N methyl pentane Natural products CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 2
- WKTJARICUXIGKW-UHFFFAOYSA-N n-methyl-3-(trifluoromethoxy)aniline Chemical compound CNC1=CC=CC(OC(F)(F)F)=C1 WKTJARICUXIGKW-UHFFFAOYSA-N 0.000 description 2
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 201000001976 pemphigus vulgaris Diseases 0.000 description 2
- XNLICIUVMPYHGG-UHFFFAOYSA-N pentan-2-one Chemical compound CCCC(C)=O XNLICIUVMPYHGG-UHFFFAOYSA-N 0.000 description 2
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 229910000160 potassium phosphate Inorganic materials 0.000 description 2
- 235000011009 potassium phosphates Nutrition 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- UDJFFSGCRRMVFH-UHFFFAOYSA-N pyrido[2,3-d]pyrimidine Chemical compound N1=CN=CC2=CC=CN=C21 UDJFFSGCRRMVFH-UHFFFAOYSA-N 0.000 description 2
- PAQYIEZTLSDLQO-UHFFFAOYSA-N pyrido[3,4-d]pyrimidine Chemical compound N1=CN=C2C=NC=CC2=C1 PAQYIEZTLSDLQO-UHFFFAOYSA-N 0.000 description 2
- PLZDHJUUEGCXJH-UHFFFAOYSA-N pyrido[4,3-d]pyrimidine Chemical compound C1=NC=C2C=NC=CC2=N1 PLZDHJUUEGCXJH-UHFFFAOYSA-N 0.000 description 2
- 150000003921 pyrrolotriazines Chemical class 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 230000036303 septic shock Effects 0.000 description 2
- 201000005113 shigellosis Diseases 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 125000006000 trichloroethyl group Chemical group 0.000 description 2
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 2
- 125000004205 trifluoroethyl group Chemical class [H]C([H])(*)C(F)(F)F 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- 201000008827 tuberculosis Diseases 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- ULQYAUYZMHHCIN-UHFFFAOYSA-N (2-cyclopentyloxy-5-fluorophenyl)methanamine Chemical compound NCC1=CC(F)=CC=C1OC1CCCC1 ULQYAUYZMHHCIN-UHFFFAOYSA-N 0.000 description 1
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 description 1
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 description 1
- 125000003837 (C1-C20) alkyl group Chemical group 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- 125000006652 (C3-C12) cycloalkyl group Chemical group 0.000 description 1
- OTPDWCMLUKMQNO-UHFFFAOYSA-N 1,2,3,4-tetrahydropyrimidine Chemical compound C1NCC=CN1 OTPDWCMLUKMQNO-UHFFFAOYSA-N 0.000 description 1
- FYADHXFMURLYQI-UHFFFAOYSA-N 1,2,4-triazine Chemical compound C1=CN=NC=N1 FYADHXFMURLYQI-UHFFFAOYSA-N 0.000 description 1
- CDCHBOQVXIGZHA-UHFFFAOYSA-N 1,2-dihydropyrrol-5-one Chemical compound O=C1NCC=C1 CDCHBOQVXIGZHA-UHFFFAOYSA-N 0.000 description 1
- VIESAWGOYVNHLV-UHFFFAOYSA-N 1,3-dihydropyrrol-2-one Chemical compound O=C1CC=CN1 VIESAWGOYVNHLV-UHFFFAOYSA-N 0.000 description 1
- VAYTZRYEBVHVLE-UHFFFAOYSA-N 1,3-dioxol-2-one Chemical compound O=C1OC=CO1 VAYTZRYEBVHVLE-UHFFFAOYSA-N 0.000 description 1
- ABADUMLIAZCWJD-UHFFFAOYSA-N 1,3-dioxole Chemical compound C1OC=CO1 ABADUMLIAZCWJD-UHFFFAOYSA-N 0.000 description 1
- PHGMUOJCQCLPBD-UHFFFAOYSA-N 1-(1-bromoethyl)-4-fluorobenzene Chemical compound CC(Br)C1=CC=C(F)C=C1 PHGMUOJCQCLPBD-UHFFFAOYSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 1
- UCNGGGYMLHAMJG-UHFFFAOYSA-N 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole Chemical compound C1=NN(C)C=C1B1OC(C)(C)C(C)(C)O1 UCNGGGYMLHAMJG-UHFFFAOYSA-N 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
- HYZJCKYKOHLVJF-SFIIULIVSA-N 1H-benzimidazole Chemical class C1=CC=C2N[11CH]=NC2=C1 HYZJCKYKOHLVJF-SFIIULIVSA-N 0.000 description 1
- 125000003562 2,2-dimethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- MXILHVKNAYIRPJ-UHFFFAOYSA-N 2,3,7,7a-tetrahydro-1h-triazolo[4,5-b]pyrazine Chemical class N1C=CN=C2NNNC21 MXILHVKNAYIRPJ-UHFFFAOYSA-N 0.000 description 1
- OXBLVCZKDOZZOJ-UHFFFAOYSA-N 2,3-Dihydrothiophene Chemical compound C1CC=CS1 OXBLVCZKDOZZOJ-UHFFFAOYSA-N 0.000 description 1
- ZABMHLDQFJHDSC-UHFFFAOYSA-N 2,3-dihydro-1,3-oxazole Chemical compound C1NC=CO1 ZABMHLDQFJHDSC-UHFFFAOYSA-N 0.000 description 1
- LWTIGYSPAXKMDG-UHFFFAOYSA-N 2,3-dihydro-1h-imidazole Chemical compound C1NC=CN1 LWTIGYSPAXKMDG-UHFFFAOYSA-N 0.000 description 1
- 125000003660 2,3-dimethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000003764 2,4-dimethylpentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- OJTMHIMQUQOLJV-UHFFFAOYSA-N 2,5-difluorobenzonitrile Chemical compound FC1=CC=C(F)C(C#N)=C1 OJTMHIMQUQOLJV-UHFFFAOYSA-N 0.000 description 1
- GCRNUVFNHLFBRI-UHFFFAOYSA-N 2,5-dihydro-1h-pyridin-6-one Chemical compound O=C1CC=CCN1 GCRNUVFNHLFBRI-UHFFFAOYSA-N 0.000 description 1
- WURYWHAKEJHAOV-UHFFFAOYSA-N 2,5-dihydrothiophene Chemical compound C1SCC=C1 WURYWHAKEJHAOV-UHFFFAOYSA-N 0.000 description 1
- HSGIETILEHRRMA-UHFFFAOYSA-N 2-(1-methylpyrazol-4-yl)benzonitrile Chemical compound CN1C=C(C=N1)C1=CC=CC=C1C#N HSGIETILEHRRMA-UHFFFAOYSA-N 0.000 description 1
- MDHNVHCZDCSTMS-UHFFFAOYSA-N 2-bromo-5-fluorobenzonitrile Chemical compound FC1=CC=C(Br)C(C#N)=C1 MDHNVHCZDCSTMS-UHFFFAOYSA-N 0.000 description 1
- IMRWILPUOVGIMU-UHFFFAOYSA-N 2-bromopyridine Chemical compound BrC1=CC=CC=N1 IMRWILPUOVGIMU-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
- 125000003229 2-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- 125000004336 3,3-dimethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- ZPOODPZCZLCUAN-UHFFFAOYSA-N 3,4-dihydro-1h-pyridin-2-one Chemical compound O=C1CCC=CN1 ZPOODPZCZLCUAN-UHFFFAOYSA-N 0.000 description 1
- BRNCTEUUWQPNBJ-UHFFFAOYSA-N 3,4-dihydro-2H-1,4-thiazine 1,1-dioxide Chemical compound O=S1(=O)CCNC=C1 BRNCTEUUWQPNBJ-UHFFFAOYSA-N 0.000 description 1
- NLXFKDHULKLENC-UHFFFAOYSA-N 3,4-dihydro-2h-1,3-oxazine Chemical compound C1NCC=CO1 NLXFKDHULKLENC-UHFFFAOYSA-N 0.000 description 1
- YEEGQDGJIXWFIQ-UHFFFAOYSA-N 3,4-dihydro-2h-1,4-oxazine Chemical compound C1COC=CN1 YEEGQDGJIXWFIQ-UHFFFAOYSA-N 0.000 description 1
- VREFDQNWPNDZEX-UHFFFAOYSA-N 3,6-Dihydro-2H-pyran-2-one Chemical compound O=C1CC=CCO1 VREFDQNWPNDZEX-UHFFFAOYSA-N 0.000 description 1
- RUPLWPYHVWSFEF-UHFFFAOYSA-N 3,6-dihydro-2h-1,3-oxazine Chemical compound C1NC=CCO1 RUPLWPYHVWSFEF-UHFFFAOYSA-N 0.000 description 1
- ZQZJULZPQACTES-UHFFFAOYSA-N 3-(1h-imidazol-2-yl)pyridine Chemical compound C1=CNC(C=2C=NC=CC=2)=N1 ZQZJULZPQACTES-UHFFFAOYSA-N 0.000 description 1
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
- 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
- 125000004337 3-ethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- XDPCNPCKDGQBAN-UHFFFAOYSA-N 3-hydroxytetrahydrofuran Chemical compound OC1CCOC1 XDPCNPCKDGQBAN-UHFFFAOYSA-N 0.000 description 1
- 125000003469 3-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- QXZBMSIDSOZZHK-DOPDSADYSA-N 31362-50-2 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1NC(=O)CC1)C(C)C)C1=CNC=N1 QXZBMSIDSOZZHK-DOPDSADYSA-N 0.000 description 1
- XYVMOLOUBJBNBF-UHFFFAOYSA-N 3h-1,3-oxazol-2-one Chemical compound OC1=NC=CO1 XYVMOLOUBJBNBF-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- WQNHSCZQLLEPOM-UHFFFAOYSA-N 4-bromo-2-n-methylbenzene-1,2-diamine Chemical compound CNC1=CC(Br)=CC=C1N WQNHSCZQLLEPOM-UHFFFAOYSA-N 0.000 description 1
- XORHNJQEWQGXCN-UHFFFAOYSA-N 4-nitro-1h-pyrazole Chemical compound [O-][N+](=O)C=1C=NNC=1 XORHNJQEWQGXCN-UHFFFAOYSA-N 0.000 description 1
- DXJKRLHHCGXHMB-UHFFFAOYSA-N 5,6,7,8-tetrahydro-[1,2,4]triazolo[1,5-a]pyrazine Chemical class C1NCCN2N=CN=C21 DXJKRLHHCGXHMB-UHFFFAOYSA-N 0.000 description 1
- QGFYFOHMBDMGBZ-UHFFFAOYSA-N 5-[(7-chloroquinolin-4-yl)amino]-2-(diethylaminomethyl)phenol Chemical compound C1=C(O)C(CN(CC)CC)=CC=C1NC1=CC=NC2=CC(Cl)=CC=C12 QGFYFOHMBDMGBZ-UHFFFAOYSA-N 0.000 description 1
- HMRSJGDFTOUVBW-UHFFFAOYSA-N 5-bromo-1,3-benzoxazol-2-amine Chemical compound BrC1=CC=C2OC(N)=NC2=C1 HMRSJGDFTOUVBW-UHFFFAOYSA-N 0.000 description 1
- BCALQXIOWJBFIQ-UHFFFAOYSA-N 5-fluoro-2-formylbenzonitrile Chemical compound FC1=CC=C(C=O)C(C#N)=C1 BCALQXIOWJBFIQ-UHFFFAOYSA-N 0.000 description 1
- 125000004070 6 membered heterocyclic group Chemical group 0.000 description 1
- APUYIVHTTCCVMF-UHFFFAOYSA-N 6-bromo-1,3-benzoxazol-2-amine Chemical compound C1=C(Br)C=C2OC(N)=NC2=C1 APUYIVHTTCCVMF-UHFFFAOYSA-N 0.000 description 1
- VEHNVCGISXDBIG-UHFFFAOYSA-N 6-chloroimidazo[1,2-b]pyridazin-2-amine Chemical compound N1=C(Cl)C=CC2=NC(N)=CN21 VEHNVCGISXDBIG-UHFFFAOYSA-N 0.000 description 1
- MPZDNIJHHXRTIQ-UHFFFAOYSA-N 6-chloroimidazo[1,2-b]pyridazine Chemical compound N1=C(Cl)C=CC2=NC=CN21 MPZDNIJHHXRTIQ-UHFFFAOYSA-N 0.000 description 1
- VHVKJEPMBOPRJQ-UHFFFAOYSA-N 7-bromo-2-methyl-[1,2,4]triazolo[1,5-a]pyridine Chemical compound C1=C(Br)C=CN2N=C(C)N=C21 VHVKJEPMBOPRJQ-UHFFFAOYSA-N 0.000 description 1
- NDIKNFVRYGSZTL-UHFFFAOYSA-N 7-bromo-N,N-bis[(4-methoxyphenyl)methyl]-5-(trifluoromethyl)pyrrolo[2,1-f][1,2,4]triazin-4-amine Chemical compound COC1=CC=C(CN(CC2=CC=C(OC)C=C2)C2=NC=NN3C(Br)=CC(=C23)C(F)(F)F)C=C1 NDIKNFVRYGSZTL-UHFFFAOYSA-N 0.000 description 1
- VGJYOOVSVQHZPL-UHFFFAOYSA-N 7-bromo-[1,2,4]triazolo[1,5-a]pyridine Chemical compound C1=C(Br)C=CN2N=CN=C21 VGJYOOVSVQHZPL-UHFFFAOYSA-N 0.000 description 1
- YGCJBESZJIGDMP-UHFFFAOYSA-N 7-bromopyrrolo[2,1-f][1,2,4]triazin-4-amine Chemical compound NC1=NC=NN2C(Br)=CC=C12 YGCJBESZJIGDMP-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 206010055128 Autoimmune neutropenia Diseases 0.000 description 1
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 102000013585 Bombesin Human genes 0.000 description 1
- 108010051479 Bombesin Proteins 0.000 description 1
- 208000008720 Bone Marrow Neoplasms Diseases 0.000 description 1
- YTAWDIATAWLOMI-UHFFFAOYSA-N C1(=CC(=CC=C1C1=CN(N=C1)C)F)CN1C(=O)C2=C(N=CC(Br)=C2)CC1 Chemical compound C1(=CC(=CC=C1C1=CN(N=C1)C)F)CN1C(=O)C2=C(N=CC(Br)=C2)CC1 YTAWDIATAWLOMI-UHFFFAOYSA-N 0.000 description 1
- AEHXKQADIZQTNS-UHFFFAOYSA-N C1=C(F)C=C(C(=C1CN1C(=O)C2=C(N=CC(=C2)Br)CC1)OC1CCOCC1)F Chemical compound C1=C(F)C=C(C(=C1CN1C(=O)C2=C(N=CC(=C2)Br)CC1)OC1CCOCC1)F AEHXKQADIZQTNS-UHFFFAOYSA-N 0.000 description 1
- NIGPBSZVHOOOGS-UHFFFAOYSA-N C1CCNCC1.O=C1C=CC=CN1 Chemical compound C1CCNCC1.O=C1C=CC=CN1 NIGPBSZVHOOOGS-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 101710167800 Capsid assembly scaffolding protein Proteins 0.000 description 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 1
- 208000006029 Cardiomegaly Diseases 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010063094 Cerebral malaria Diseases 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 108010072757 Death Domain Receptor Signaling Adaptor Proteins Proteins 0.000 description 1
- 102000006999 Death Domain Receptor Signaling Adaptor Proteins Human genes 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 102000007443 Deubiquitinating Enzyme CYLD Human genes 0.000 description 1
- 108010086291 Deubiquitinating Enzyme CYLD Proteins 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 102100030013 Endoribonuclease Human genes 0.000 description 1
- 101710199605 Endoribonuclease Proteins 0.000 description 1
- 208000037487 Endotoxemia Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- STXVOQOSKVHZOR-UHFFFAOYSA-N FC(C=C1)=CC(CN(CC2)CC3=C2N=CC(Br)=C3)=C1OC1CCOCC1 Chemical compound FC(C=C1)=CC(CN(CC2)CC3=C2N=CC(Br)=C3)=C1OC1CCOCC1 STXVOQOSKVHZOR-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000015872 Gaucher disease Diseases 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 206010018634 Gouty Arthritis Diseases 0.000 description 1
- 239000007821 HATU Substances 0.000 description 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 206010019755 Hepatitis chronic active Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001011663 Homo sapiens Mixed lineage kinase domain-like protein Proteins 0.000 description 1
- 101001099058 Homo sapiens Serine/threonine-protein phosphatase PGAM5, mitochondrial Proteins 0.000 description 1
- 101000595548 Homo sapiens TIR domain-containing adapter molecule 1 Proteins 0.000 description 1
- 101000831496 Homo sapiens Toll-like receptor 3 Proteins 0.000 description 1
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 1
- 101000610605 Homo sapiens Tumor necrosis factor receptor superfamily member 10A Proteins 0.000 description 1
- 101000610604 Homo sapiens Tumor necrosis factor receptor superfamily member 10B Proteins 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108010034143 Inflammasomes Proteins 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical class NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000015439 Lysosomal storage disease Diseases 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102100030177 Mixed lineage kinase domain-like protein Human genes 0.000 description 1
- 206010028289 Muscle atrophy Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- LYVYGUWQITYCHY-UHFFFAOYSA-N N1N=CC=C1.O1N=CC=N1 Chemical compound N1N=CC=C1.O1N=CC=N1 LYVYGUWQITYCHY-UHFFFAOYSA-N 0.000 description 1
- IDMXFLHVIIINPE-UHFFFAOYSA-N NCC(C=C(C=C1F)F)=C1OC1COCC1 Chemical compound NCC(C=C(C=C1F)F)=C1OC1COCC1 IDMXFLHVIIINPE-UHFFFAOYSA-N 0.000 description 1
- 108010014632 NF-kappa B kinase Proteins 0.000 description 1
- 102100023050 Nuclear factor NF-kappa-B p105 subunit Human genes 0.000 description 1
- CAYLSBXWHLNADU-UHFFFAOYSA-N O1C=NN=C1.N1N=CC=C1 Chemical compound O1C=NN=C1.N1N=CC=C1 CAYLSBXWHLNADU-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 101710130420 Probable capsid assembly scaffolding protein Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000033464 Reiter syndrome Diseases 0.000 description 1
- 206010061481 Renal injury Diseases 0.000 description 1
- 206010063897 Renal ischaemia Diseases 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 206010038848 Retinal detachment Diseases 0.000 description 1
- 208000007014 Retinitis pigmentosa Diseases 0.000 description 1
- 101710204410 Scaffold protein Proteins 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 206010053879 Sepsis syndrome Diseases 0.000 description 1
- 101710113029 Serine/threonine-protein kinase Proteins 0.000 description 1
- 102100038901 Serine/threonine-protein phosphatase PGAM5, mitochondrial Human genes 0.000 description 1
- 201000010001 Silicosis Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 102100036073 TIR domain-containing adapter molecule 1 Human genes 0.000 description 1
- 108090000925 TNF receptor-associated factor 2 Proteins 0.000 description 1
- 102100034779 TRAF family member-associated NF-kappa-B activator Human genes 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010043781 Thyroiditis chronic Diseases 0.000 description 1
- 101150009046 Tnfrsf1a gene Proteins 0.000 description 1
- 102100024324 Toll-like receptor 3 Human genes 0.000 description 1
- 102100039360 Toll-like receptor 4 Human genes 0.000 description 1
- 206010044248 Toxic shock syndrome Diseases 0.000 description 1
- 231100000650 Toxic shock syndrome Toxicity 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- 206010048873 Traumatic arthritis Diseases 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- 102100040113 Tumor necrosis factor receptor superfamily member 10A Human genes 0.000 description 1
- 102100040112 Tumor necrosis factor receptor superfamily member 10B Human genes 0.000 description 1
- 101710187743 Tumor necrosis factor receptor superfamily member 1A Proteins 0.000 description 1
- 102100033732 Tumor necrosis factor receptor superfamily member 1A Human genes 0.000 description 1
- 241000282458 Ursus sp. Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- WJEIYVAPNMUNIU-UHFFFAOYSA-N [Na].OC(O)=O Chemical compound [Na].OC(O)=O WJEIYVAPNMUNIU-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 231100000354 acute hepatitis Toxicity 0.000 description 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 150000001483 arginine derivatives Chemical class 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 201000005000 autoimmune gastritis Diseases 0.000 description 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 201000006491 bone marrow cancer Diseases 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- VIHAEDVKXSOUAT-UHFFFAOYSA-N but-2-en-4-olide Chemical compound O=C1OCC=C1 VIHAEDVKXSOUAT-UHFFFAOYSA-N 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000007942 carboxylates Chemical group 0.000 description 1
- 230000006041 cell recruitment Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- ZOOSILUVXHVRJE-UHFFFAOYSA-N cyclopropanecarbonyl chloride Chemical compound ClC(=O)C1CC1 ZOOSILUVXHVRJE-UHFFFAOYSA-N 0.000 description 1
- YOXHCYXIAVIFCZ-UHFFFAOYSA-N cyclopropanol Chemical compound OC1CC1 YOXHCYXIAVIFCZ-UHFFFAOYSA-N 0.000 description 1
- 210000005220 cytoplasmic tail Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 230000009504 deubiquitination Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- TWXWPPKDQOWNSX-UHFFFAOYSA-N dicyclohexylmethanone Chemical class C1CCCCC1C(=O)C1CCCCC1 TWXWPPKDQOWNSX-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000003821 enantio-separation Methods 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 1
- 125000005349 heteroarylcycloalkyl group Chemical group 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- VTVRXITWWZGKHV-UHFFFAOYSA-N imidazo[1,2-b]pyridazine Chemical compound N1=CC=CC2=NC=CN21 VTVRXITWWZGKHV-UHFFFAOYSA-N 0.000 description 1
- 150000004942 imidazo[1,2-b]pyridazines Chemical class 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 150000005235 imidazopyrazines Chemical class 0.000 description 1
- 150000005233 imidazopyridazines Chemical class 0.000 description 1
- 150000003949 imides Chemical class 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 201000003866 lung sarcoma Diseases 0.000 description 1
- 230000029849 luteinization Effects 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 125000002911 monocyclic heterocycle group Chemical group 0.000 description 1
- RCDZLUOFXDDLDV-UHFFFAOYSA-N morpholine;1h-pyrrole Chemical compound C=1C=CNC=1.C1COCCN1 RCDZLUOFXDDLDV-UHFFFAOYSA-N 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 238000006384 oligomerization reaction Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- MUJIDPITZJWBSW-UHFFFAOYSA-N palladium(2+) Chemical compound [Pd+2] MUJIDPITZJWBSW-UHFFFAOYSA-N 0.000 description 1
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 210000000608 photoreceptor cell Anatomy 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 238000004237 preparative chromatography Methods 0.000 description 1
- 230000007112 pro inflammatory response Effects 0.000 description 1
- 230000001686 pro-survival effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- LDIJKUBTLZTFRG-UHFFFAOYSA-N pyrazolo[1,5-a]pyrimidine Chemical compound N1=CC=CN2N=CC=C21 LDIJKUBTLZTFRG-UHFFFAOYSA-N 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 208000002574 reactive arthritis Diseases 0.000 description 1
- 230000033300 receptor internalization Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000004264 retinal detachment Effects 0.000 description 1
- 208000032253 retinal ischemia Diseases 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 208000015891 sexual disease Diseases 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- 241000894007 species Species 0.000 description 1
- VNFWTIYUKDMAOP-UHFFFAOYSA-N sphos Chemical group COC1=CC=CC(OC)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 VNFWTIYUKDMAOP-UHFFFAOYSA-N 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 201000004595 synovitis Diseases 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000009772 tissue formation Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000009529 traumatic brain injury Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 150000008523 triazolopyridines Chemical class 0.000 description 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Abstract
Description
化合物编号 | U937 IC 50(μM) | 化合物编号 | U937 IC 50(μM) |
Z5 | 0.0467 | Z59 | 0.012 |
Z6 | 0.0004 | Z60 | 0.162 |
Z7 | 0.0039 | Z61 | 0.014 |
Z8 | 0.0403 | Z62 | 0.013 |
Z9 | 0.0104 | Z64 | 0.002 |
Z1 | 0.0028 | Z65 | 0.0005 |
Z10 | 0.0059 | Z66 | 0.0023 |
Z2 | 0.000103 | Z67 | 0.0005 |
Z3 | 0.0014 | Z68 | 0.0043 |
Z11 | 0.0312 | Z69 | 0.0014 |
Z13 | 0.0017 | Z70 | 0.0004 |
Z14 | 0.0102 | Z71 | 0.0011 |
Z16 | 0.0107 | Z72 | 0.082 |
Z17 | 0.0575 | Z73 | 0.034 |
Z18 | 0.0702 | Z74 | 0.0038 |
Z19 | 0.0347 | Z76 | 0.0041 |
Z20 | 0.0044 | Z77 | 0.1434 |
Z21 | 0.0006 | Z78 | 0.0595 |
Z23 | 0.0243 | Z79 | 0.0476 |
Z24 | 0.0365 | Z80 | 0.0198 |
Z27 | 0.0060 | Z82 | 0.0234 |
Z27-2 | 0.0019 | Z85 | 0.0043 |
Z28 | 0.0127 | Z33 | 0.3382 |
Z31 | 0.0182 | Z37 | 0.0005 |
Z36 | 0.0453 | Z32 | 0.0268 |
Z44 | 0.042 | Z30 | 0.0091 |
Z45 | 0.0002 | Z38 | 0.0013 |
Z46 | 0.007 | Z35 | 0.0003 |
Z46-1 | 0.0074 | Z94 | 0.0025 |
Z46-2 | 0.9857 | Z39 | 0.0009 |
Z47 | 0.003 | Z96 | 0.0017 |
Z48 | 0.006 | Z31-1 | 0.0074 |
Z49 | 0.026 | Z35-1 | 0.0003 |
Z50 | 0.040 | Z35-2 | 0.0002 |
Z51 | 0.024 | Z30-2 | 0.0034 |
Z52 | 0.019 | Z97 | 0.0002 |
Z54 | 0.012 | Z93 | 0.013 |
Z55 | 0.008 | Z102 | 0.0211 |
Z56 | 0.004 | Z98 | 0.4174 |
Z57 | 0.002 |
化合物编号 | RIPK1酶IC 50(nM) | 化合物编号 | RIPK1酶IC 50(nM) |
Z48 | 39 | Z69 | 33 |
Z10 | 56 | Z2 | 37 |
Z51 | 72 | Z74 | 193 |
Z82 | 50 | Z85 | 34 |
化合物编号 | L929IC 50(μM) | 化合物编号 | L929IC 50(μM) |
Z44 | 0.0092 | Z69 | 0.0037 |
Z45 | 0.0013 | Z10 | 0.0024 |
Z46 | 0.0029 | Z2 | <0.0028 |
Z47 | 0.0051 | Z74 | 0.0023 |
Z5 | 0.0080 | Z85 | 0.0134 |
Z48 | 0.0030 |
Claims (15)
- 一种二氢萘啶酮化合物,或其药学上可接受的盐、立体异构体、溶剂化物或前药,其特征在于,所述化合物的结构如式(I)所示:式中,R 1、R 2各自独立地为氢、卤素、取代或未取代的C 1-6烷基、取代或未取代的C 1-6烷氧基或取代或未取代的NR a0R b0;其中,R a0、R b0各自独立地为氢或C 1-3烷基;或者R a0、R b0与相连的氮原子共同形成3至8元含氮杂环烷基;R 1、R 2中所述的“取代”是指基团中的1、2、3或4个氢原子被各自独立地选自S组取代基所取代;R 3、R 4、R 5、R 6的定义选自下组中的一种:(i)R 3、R 4、R 5、R 6各自独立地为氢、卤素、取代或未取代的C 1-6烷基、或取代或未取代的C 3-8环烷基;所述的“取代”是指基团中的1、2、3或4个氢原子被各自独立地选自S组取代基所取代;(ii)R 3、R 4与相连的碳原子共同形成取代或未取代的C 3-8环烷基环或取代或未取代的3至6元杂环烷基环;R 5、R 6各自独立地为氢、卤素、取代或未取代的C 1-6烷基、或取代或未取代的C 3-8环烷基;所述的“取代”是指基团中的1、2、3或4个氢原子被各自独立地选自S组取代基所取代;(iii)R 3、R 4各自独立地为氢、卤素、取代或未取代的C 1-6烷基、或取代或未取代的C 3-8环烷基;R 5、R 6与相连的碳原子共同形成取代或未取代的C 3-8环烷基环或取代或未取代的3至6元杂环烷基环;所述的“取代”是指基团中的1、2、3或4个氢原子被各自独立地选自S组取代基所取代;(iv)R 4、R 5与相连的碳原子共同形成取代或未取代的C 3-8环烷基环或取代或未取代的3至6元杂环烷基环;R 3、R 6各自独立地为氢、卤素、取代或未取代的C 1-6烷基、或取代或未取代的C 3-8环烷基;所述的“取代”是指基团中的1、2、3或4个氢原子被各自独立地选自S组取代基所取代;B为-L-R 0;其中,R 0为取代或未取代的C 6-14芳基、取代或未取代的5至14元杂芳基或取代或未取代的5至14元杂环烷基;R 0中所述的“取代”是指基团中的1、2、3或4个氢原子被各自独立地选自S组取代基所取代;L为一个键、-(CR 11R 12) t1-(CR 21R 22) t2-(CR 31R 32) t3-(CR 41R 42) t4-(O) t5-或-(CR 13R 14) t1-(CR 23R 24) t2-(NR 33) t3-(CR 43R 44) t4-(O) t5-;其中t1、t2、t3、t4、t5各自独立地为0或1;R 11、R 12、R 21、R 22、R 31、R 32、R 41、R 42的定义选自下组中的一种:(a2)R 11、R 12、R 41、R 42各自独立地为氢、氘、卤素、羟基、羟甲基、羟乙基或C 1-3烷基;R 21、R 22、R 31、R 32各自独立地为氢、氘、卤素、羟基、羟甲基、羟乙基或C 1-3烷基;(b2)R 11、R 12、R 41、R 42各自独立地为氢、氘、卤素、羟基、羟甲基、羟乙基或C 1-3烷基;R 21、R 22与相连的碳原子共同形成取代或未取代的C 3-8环烷基环或取代或未取代的3至6元杂环烷基环;所述的“取代”是指基团中的1、2、3或4个氢原子被各自独立地选自S组取代基所取代;R 31、R 32各自独立地为氢、氘、卤素、羟基、羟甲基、羟乙基或C 1-3烷基;(c2)R 11、R 12、R 41、R 42各自独立地为氢、氘、卤素、羟基、羟甲基、羟乙基或C 1-3烷基;R 21、R 22各自独立地为氢、氘、卤素、羟基、羟甲基、羟乙基或C 1-3烷基;R 31、R 32与相连的碳原子共同形成取代或未取代的C 3-8环烷基环或取代或未取代的3至6元杂环烷基环;所述的“取代”是指基团中的1、2、3或4个氢原子被各自独立地选自S组取代基所取代;(d2)R 11、R 12、R 41、R 42各自独立地为氢、氘、卤素、羟基、羟甲基、羟乙基或C 1-3烷基;R 22、R 32各自独立地为氢、氘、卤素、羟基、羟甲基、羟乙基或C 1-3烷基;R 21、R 31与相连的原子共同形成取代或未取代的C 3-8环烷基环或取代或未取代的3至6元杂环烷基环;所述的“取代”是指基团中的1、2、3或4个氢原子被各自独立地选自S组取代基所取代;(e2)R 12、R 41、R 42各自独立地为氢、氘、卤素、羟基、羟甲基、羟乙基或C 1-3烷基;R 21、R 22、R 32各自独立地为氢、氘、卤素、羟基、羟甲基、羟乙基或C 1-3烷基;R 11与R 31与相连的原子共同形成取代或未取代的C 3-8环烷基环或取代或未取代的3至6元杂环烷基环;所述的“取代”是指基团中的1、2、3或4个氢原子被各自独立地选自S组取代基所取代;R 13、R 14、R 23、R 24、R 33、R 43、R 44的定义选自下组中的一种:(a3)R 13、R 14、R 23、R 24、R 43、R 44各自独立地为氢、氘、卤素、羟基、羟甲基、羟乙基或C 1-3烷基;R 33为氢、氘、羟甲基、羟乙基或C 1-3烷基;(b3)R 13、R 14、R 43、R 44各自独立地为氢、氘、卤素、羟基、羟甲基、羟乙基或C 1-3烷基;R 23、R 24与相连的碳原子共同形成取代或未取代的C 3-8环烷基环或取代或未取代的3至6元杂环烷基环;所述的“取代”是指基团中的1、2、3或4个氢原子被各自独立地选自S组取代基所取代;R 33为氢、氘、羟甲基、羟乙基或C 1-3烷基;(c3)R 13、R 14、R 23、R 43、R 44各自独立地为氢、氘、卤素、羟基、羟甲基、羟乙基或C 1-3烷基;R 24、R 33与相连的原子共同形成取代或未取代的3至6元含氮杂环烷基环;所述的“取代”是指基团中的1、2、3或4个氢原子被各自独立地选自S组取代基所取代;(d3)R 13、R 23、R 24、R 43、R 44各自独立地为氢、氘、卤素、羟基、羟甲基、羟乙基或C 1-3烷基;R 14、R 33与相连的原子共同形成取代或未取代的3至6元含氮杂环烷基环;所述的“取代”是指基团中的1、2、3或4个氢原子被各自独立地选自S组取代基所取代;A为(i)取代或未取代的5或6元单杂芳基;其中所述的“取代”是指基团中的1、2、3或4个氢原子被各自独立地选自S组取代基所取代;(ii)取代或未取代的8至10元双杂芳基;所述8至10元双杂芳基是由5或6元单杂芳基环与5或6元单杂芳基环稠合形成;其中所述的“取代”是指基团中的1、2、3或4个氢原子被各自独立地选自S组取代基所取代;(iii)取代或未取代的9或10元双杂芳基;所述9或10元双杂芳基是由苯环与5或6元单杂芳基环稠合形成;其中所述5或6元单杂芳基环选自下组:(ⅳ)取代或未取代的8至10元双杂芳基;所述8至10元双杂芳基是由5或6元单杂芳基环与一个5或6元单环杂环烷基环稠合形成;其中所述的“取代”是指基团中的1、2、3或4个氢原子被各自独立地选自S组取代基所取代;或者(ⅴ)取代或未取代的苯并噻唑;其中所述的“取代”是指基团中的1、2、3或4个氢原子被各自独立地选自S’组取代基所取代;上述基团中,所述S组取代基选自:氘、卤素、硝基、氧代基、-C 1-6烷基、-卤代C 1-6烷基、-氘代C 1-6烷基、-S-C 1-6烷基、-S-卤代C 1-6烷基、-(CR a1R b1) u-氰基、-(CR a1R b1) u-羟基、-(CR a1R b1) u-C 1-6烷氧基、-(CR a1R b1) u-卤代C 1-6烷氧基、-(CR a1R b1) u-氘代C 1-6烷氧基、-(CR a1R b1) u-卤代C 1-6烷基、-(CR a1R b1) u-氘代C 1-6烷基、-(CR a1R b1) u-3至6元杂环烷基、-(CR a1R b1) u-C 3-8环烷基、-(CR a1R b1) u-苯基、-(CR a1R b1) u-5或6元单环杂芳基、-(CR a1R b1) u-O-(CR a2R b2) v-卤代C 1-6烷基、-(CR a1R b1) u-O-(CR a2R b2) v-C 3-8环烷基、-(CR a1R b1) u-O-(CR a2R b2) v-3至6元杂环烷基、-(CR a1R b1) u-O-(CR a2R b2) v-苯基、-(CR a1R b1) u-O-(CR a2R b2) v-5或6元单环杂芳基、-(CR a1R b1) u-S-(CR a2R b2) v-苯基、-(CR a1R b1) u-SO 2-(CR a2R b2) v-苯基、-(CR a1R b1) u-O-C(O)NR a0R b0、-(CR a1R b1) u-O-(CR a2R b2) v-C 1-6 烷氧基、-(CR a1R b1) u-O-(CR a2R b2) v-羟基、-(CR a1R b1) u-SO 2C 1-6烷基、-(CR a1R b1) u-SO 2NR a0R b0、-(CR a1R b1) u-C(O)NR a0R b0、-(CR a1R b1) u-C(O)苯基、-(CR a1R b1) u-C(O)C 1-6烷基、-C(O)OC 1-6烷基、-C(O)-(CR a2R b2) v-羟基、-(CR a1R b1) u-NR a0R b0、-NR a0C(O)-C 1-6烷基、-NR a0C(O)-氘代C 1-6烷基、-NR a0C(O)-(CR a1R b1) u-羟基、-NR a0C(O)-(CR a1R b1) u-O-(CR a2R b2) v-C(O)C 1-6烷基、-NR a0C(O)-(CR a1R b1) u-O-(CR a2R b2) v-苯基、-NR a0C(O)-C 3-8环烷基、-NR a0C(O)-(CR a1R b1) u-NR a0R b0、-NR a0C(O)-卤代C 1-6烷基;其中所述C 3-8环烷基、3至6元杂环烷基、苯基、5或6元单环杂芳基任选地被1、2或3个选自羟基、羟甲基、羟乙基、卤素、氰基、氰基甲基、氰基乙基、C 1-3烷基、卤代C 1-3烷基、C 1-3烷氧基、卤代C 1-3烷氧基、C 3-6环烷基和卤代C 3-6环烷基的取代基取代;u、v各自独立地为0、1、2、3或4;R a0、R b0各自独立地为氢或C 1-3烷基;或者R a0、R b0与相连的氮原子共同形成3至8元含氮杂环烷基,所述3至8元含氮杂环烷基任选地被1、2或3个卤素或C 1-3烷基取代;R a1、R b1、R a2、R b2相同或不同,各自独立地为氢、羟基、C 1-3烷基或卤代C 1-3烷基;上述基团中,所述S’组取代基选自:氘、卤素、硝基、氧代基、-C 1-6烷基、-卤代C 1-6烷基、-氘代C 1-6烷基、-S-C 1-6烷基、-S-卤代C 1-6烷基、-(CR a1’R b1’) u’-氰基、-(CR a1’R b1’) u’-羟基、-(CR a1’R b1’) u’-C 1-6烷氧基、-(CR a1’R b1’) u’-卤代C 1-6烷氧基、-(CR a1’R b1’) u’-卤代C 1-6烷基、-(CR a1’R b1’) u’-3至6元杂环烷基、-(CR a1’R b1’) u’-C 3-8环烷基、-(CR a1’R b1’) u’-苯基、-(CR a1’R b1’) u’-5或6元单环杂芳基、-(CR a1’R b1’) u’-O-(CR a2’R b2’) v’-卤代C 1-6烷基、-(CR a1’R b1’) u’-O-(CR a2’R b2’) v’-C 3-8环烷基、-(CR a1’R b1’) u’-O-(CR a2’R b2’) v’-3至6元杂环烷基、-(CR a1’R b1’) u’-O-(CR a2’R b2’) v-苯基、-(CR a1’R b1’) u’-O-(CR a2’R b2’) v’-5或6元单环杂芳基、-(CR a1’R b1’) u-S-(CR a2’R b2’) v’-苯基、-(CR a1’R b1’) u’-SO 2-(CR a2’R b2’) v’-苯基、-(CR a1’R b1’) u’-O-C(O)NR a0’R b0’、-(CR a1’R b1’) u’-O-(CR a2’R b2’) v’-C 1-6烷氧基、-(CR a1’R b1’) u’-O-(CR a2’R b2’) v’-羟基、-(CR a1’R b1’) u’-SO 2C 1-6烷基、-(CR a1’R b1’) u’-SO 2NR a0’R b0’、-(CR a1’R b1’) u’-C(O)NR a0’R b0’、-(CR a1’R b1’) u’-C(O)苯基、-(CR a1’R b1’) u’-C(O)C 1-6烷基、-C(O)OC 1-6烷基、-C(O)-(CR a2’R b2’) v’-羟基;其中所述C 3-8环烷基、3至6元杂环烷基、苯基、5或6元单环杂芳基任选地被1、2或3个选自羟基、羟甲基、羟乙基、卤素、氰基、氰基甲基、氰基乙基、C 1-3烷基、卤代C 1-3烷基、C 1-3烷氧基、卤代C 1-3烷氧基、C 3-6环烷基和卤代C 3-6环烷基的取代基取代;u’、v’各自独立地为0、1、2、3或4;R a0’、R b0’各自独立地为氢或C 1-3烷基;或者R a0’、R b0’与相连的氮原子共同形成3至8元含氮杂环烷基,所述3至8元含氮杂环烷基任选地被1、2或3个卤素或C 1-3烷基取代;R a1’、R b1’、R a2’、R b2’相同或不同,各自独立地为氢、羟基、C 1-3烷基或卤代C 1-3烷基。
- 如权利要求1所述的化合物、或其药学上可接受的盐、立体异构体、溶剂化合物或前药,其特征在于,A中所述由5或6元单杂芳基环与5或6元单杂芳基环稠合形成的8至10元双杂芳基为式(A1)、式(A2)或式(A3)所示的结构;其中,Z 1为N或CR Z1;Z 2为NR Z2或O;Z 3为N或CR Z3;Z 4为N或CR Z4;Z 5为N 或CR Z5;Z 6为N或CR Z6;且Z 3、Z 4、Z 5、Z 6不同时为N;且Z 3、Z 4、Z 5、Z 6中至少一个为N;Y 1为N或CR Y1;Y 2为N或CR Y2;Y 3为N或CR Y3;Y 4为N或CR Y4;Y 5为N或CR Y5;Y 6为N或CR Y6;Y 7为N或CR Y7;且Y 3、Y 4、Y 5、Y 6、Y 7不同时为N;且Y 1、Y 2、Y 3、Y 4、Y 5、Y 6、Y 7中至少一个为N;U 1为N或CR U1;U 2为N或CR U2;U 3为N或CR U3;U 4为N或CR U4;U 5为N或CR U5;U 6为N或CR U6;U 7为N或CR U7;U 8为N或CR U8;且U 4、U 5、U 6、U 7、U 8不同时为N;且U 1、U 2、U 3、U 4、U 5、U 6、U 7、U 8中至少一个为N;R Z0、R Y0、R Z1、R Z2、R Z3、R Z4、R Z5、R Z6、R Y1、R Y2、R Y3、R Y4、R Y5、R Y6、R Y7、R U1、R U2、R U3、R U4、R U5、R U6、R U7、R U8各自独立地为氢或S组取代基。
- 如权利要求1所述的化合物、或其药学上可接受的盐、立体异构体、溶剂化合物或前药,其特征在于,A中所述由5或6元单杂芳基环与一个5或6元单环杂环烷基环稠合形成的8至10元双杂芳基为式(A5)所示结构:其中,G 1为N或CR G1;G 2为N或CR G2;G 3为N或CR G3;G 4为NR G4a、O或CR G4bR G4c;G 5为NR G5a、O或CR G5bR G5c;G 6为NR G6a、O或CR G6bR G6c;G 7为NR G7a、O或CR G7bR G7c;且G 3、G 4、G 5、G 6、G 7中至少一个为N;且-G 3-G 4-G 5-G 6-G 7-不包括-O-O-、-O-N-或-N-N-的环部分;R G0、R G1、R G2、R G3、R G4a、R G4b、R G4c、R G5a、R G5b、R G5c、R G6a、R G6b、R G6c、R G7a、R G7b、R G7c各自独立地为氢或S组取代基。
- 如权利要求1所述的化合物、或其药学上可接受的盐、立体异构体、溶剂化合物或前药,其特征在于,所述化合物的结构如式(I-1)所示:其中,i、j各自独立地为0、1或2;且i、j不同时为0;R 7为氢、氘、卤素、硝基、氧代基、-C 1-6烷基、-卤代C 1-6烷基、-氘代C 1-6烷基、-S-C 1-6烷基、-S-卤代C 1-6烷基、-(CR a1R b1) u-氰基、-(CR a1R b1) u-羟基、-(CR a1R b1) u-C 1-6烷氧基、-(CR a1R b1) u-卤代C 1-6烷氧基、-(CR a1R b1) u-卤代C 1-6烷基、-(CR a1R b1) u-氘代C 1-6烷氧基、-(CR a1R b1) u-氘代C 1-6烷基、-(CR a1R b1) u-3至6元杂环烷基、-(CR a1R b1) u-C 3-8环烷基、-(CR a1R b1) u-苯基、-(CR a1R b1) u-5或6元单环杂芳基、-(CR a1R b1) u-O-(CR a2R b2) v-卤代C 1-6烷基、-(CR a1R b1) u-O-(CR a2R b2) v-C 3-8环烷基、-(CR a1R b1) u-O-(CR a2R b2) v-3至6元杂环烷基、-(CR a1R b1) u-O-(CR a2R b2) v-苯基、-(CR a1R b1) u-O-(CR a2R b2) v-5或6元单环杂芳基、-(CR a1R b1) u-S-(CR a2R b2) v-苯基、-(CR a1R b1) u-SO 2-(CR a2R b2) v-苯基、-(CR a1R b1) u-O-C(O)NR a0R b0、-(CR a1R b1) u-O-(CR a2R b2) v-C 1-6烷氧基、-(CR a1R b1) u-O-(CR a2R b2) v-羟基、-(CR a1R b1) u-SO 2C 1-6烷基、-(CR a1R b1) u-SO 2NR a0R b0、-(CR a1R b1) u-C(O)NR a0R b0、-(CR a1R b1) u-C(O)苯基、-(CR a1R b1) u-C(O)C 1-6烷基、-C(O)OC 1-6烷基、-C(O)-(CR a2R b2) v-羟基、-(CR a1R b1) u-NR a0R b0、-NR a0C(O)-C 1-6烷基、-NR a0C(O)-氘代C 1-6烷基、-NR a0C(O)-(CR a1R b1) u-羟基、-NR a0C(O)-(CR a1R b1) u-O-(CR a2R b2) v-C(O)C 1-6烷基、-NR a0C(O)-(CR a1R b1) u-O-(CR a2R b2) v-苯基、-NR a0C(O)-C 3-8环烷基、-NR a0C(O)-(CR a1R b1) u-NR a0R b0、-NR a0C(O)-卤代C 1-6烷基;其中所述C 3-8环烷基、3至6元杂环烷基、苯基、5或6元单环杂芳基任选地被1、2或3个选自羟基、羟甲基、羟乙基、卤素、氰基、氰基甲基、氰基乙基、C 1-3烷基、卤代C 1-3烷基、C 1-3烷氧基、卤代C 1-3烷氧基、C 3-6环烷基和卤代C 3-6环烷基的取代基取代;u、v各自独立地为0、1、2、3或4;R a0、R b0各自独立地为氢或C 1-3烷基;或者R a0、R b0与相连的氮原子共同形成3至8元含氮杂环烷基,所述3至8元含氮杂环烷基任选地被1、2或3个卤素或C 1-3烷基取代;R a1、R b1、R a2、R b2相同或不同,各自独立地为氢、羟基、C 1-3烷基或卤代C 1-3烷基;R 8为氢、-(CR a1R b1) u-SO 2-(CR a2R b2) v-苯基、-(CR a1R b1) u-SO 2C 1-6烷基、-(CR a1R b1) u-SO 2NR a0R b0、-(CR a1R b1) u-C(O)NR a0R b0、-(CR a1R b1) u-C(O)苯基、-(CR a1R b1) u-C(O)C 1-6烷基、-C(O)-(CR a2R b2) v-羟基;其中,所述苯基、C 1-6烷基任选地被1、2、3或4个选自羟基、羟甲基、羟乙基、卤素、氰基、氰基甲基、氰基乙基、C 1-3烷基、卤代C 1-3烷基、C 1-3烷氧基、卤代C 1-3烷氧基、C 3-6环烷基和卤代C 3-6环烷基的取代基取代;u、v各自独立地为0、1、2、3或4;R a0、R b0各自独立地为氢或C 1-3烷基;或者R a0、R b0与相连的氮原子共同形成3至8元含氮杂环烷基;R a1、R b1、R a2、R b2相同或不同,各自独立地为氢、羟基、C 1-3烷基或卤代C 1-3烷基;其余基团定义同权利要求1。
- 如权利要求1所述的化合物、或其药学上可接受的盐、立体异构体、溶剂化合物或前药,其特征在于,R 0中,所述的C 6-14芳基为苯基、萘基、或为苯基与一个非芳香环稠合形成的9或10元芳香稠合双环;所述的非芳香环为3至6元饱和或部分不饱和单环杂环烷基或3至6元饱和或部分不饱和单环环烷基;其中,所述的3至6元饱和或部分不饱和单环杂环烷基选自:氮丙环、环氧乙烷、氮杂环丁烷、氮杂环丁烷-2-酮、氧杂环丁烷、氧杂环丁烷-2-酮、恶唑烷、吡咯烷-2-酮、吡咯烷-2,5-二酮、1,3-二氧戊环、二氢呋喃-2(3H)-酮、二氢呋喃-2,5-二酮、哌啶-2-酮、哌啶-2,6-二酮、四氢-2H-吡喃-2-酮、咪唑烷、四氢呋喃、四氢噻吩、四氢吡咯、1,3-二氧戊环-2-酮、恶唑烷-2-酮、咪唑烷-2-酮、哌啶、哌嗪、哌嗪-2-酮、吗啉、吗啉-3-酮、吗啉-2-酮、硫代吗啉-3-酮1,1-二氧化物、硫代吗啉、硫代吗啉-1,1-二氧化物、四氢吡喃、1,2-二氢氮杂环丁二烯、1,2-二氢氧杂环丁二烯、2,5-二氢-1H-吡咯、2,5-二氢呋喃、2,3-二氢呋喃、2,3-二氢-1H-吡咯、3,4-二氢-2H-吡喃、1,2,3,4-四氢吡啶、3,6-二氢-2H-吡喃、1,2,3,6-四氢吡啶、1,3-恶嗪烷、六氢嘧啶、1,4-二恶烷、四氢嘧啶-2(1H)-酮、1,4-二恶烷-2-酮、5,6-二氢-2H-吡喃-2-酮;所述的3至6元饱和或部分不饱和单环环烷基选自:环丙基、环丁基、环戊基、环戊烯基、环己基、环己烯基、环己二烯基、环丁酮、环丁烷-1,2-二酮、环戊酮、环戊烷-1,3-二酮、环己酮、环己烷-1,3-二酮;所述苯基、萘基、或9或10元芳香稠合双环为未取代的或被1、2、3或4个各自独立地选自S组取代基所取代。
- 如权利要求1所述的化合物、或其药学上可接受的盐、立体异构体、溶剂化合物 或前药,其特征在于,R 0中,所述的5至14元杂芳基为5或6元单环杂芳基;其中,所述的5或6元单环杂芳基选自:噻吩、N烷基吡咯烷酮、呋喃、噻唑、异噻唑、咪唑、噁唑、吡咯、吡唑、三唑、1,2,3-三唑、1,2,4-三唑、1,2,5-三唑、1,3,4-三唑、四唑、异噁唑、噁二唑、1,2,3-噁二唑、1,2,4-噁二唑、1,2,5-噁二唑、1,3,4-噁二唑、噻二唑、吡啶、哒嗪、嘧啶或吡嗪;所述5或6元单环杂芳基为未取代的或被1、2、3或4个各自独立地选自S组取代基所取代;或所述的5至14元杂芳基为苯基与5或6元单环杂芳基稠合形成的9或10元双环杂芳基;其中,所述的5或6元单环杂芳基选自:噻吩、N烷基吡咯烷酮、呋喃、噻唑、异噻唑、咪唑、噁唑、吡咯、吡唑、三唑、1,2,3-三唑、1,2,4-三唑、1,2,5-三唑、1,3,4-三唑、四唑、异噁唑、噁二唑、1,2,3-噁二唑、1,2,4-噁二唑、1,2,5-噁二唑、1,3,4-噁二唑、噻二唑、吡啶、哒嗪、嘧啶或吡嗪;所述9或10元双环杂芳基为未取代的或被1、2、3或4个各自独立地选自S组取代基所取代;或所述的5至14元杂芳基为5或6元单环杂芳基与5或6元单环杂芳基稠合形成的8至10元双环杂芳基;其中,所述的5或6元单环杂芳基选自:噻吩、N烷基吡咯烷酮、呋喃、噻唑、异噻唑、咪唑、噁唑、吡咯、吡唑、三唑、1,2,3-三唑、1,2,4-三唑、1,2,5-三唑、1,3,4-三唑、四唑、异噁唑、噁二唑、1,2,3-噁二唑、1,2,4-噁二唑、1,2,5-噁二唑、1,3,4-噁二唑、噻二唑、吡啶、哒嗪、嘧啶或吡嗪;所述8至10元双环杂芳基为未取代的或被1、2、3或4个各自独立地选自S组取代基所取代;或所述的5至14元杂芳基为5或6元单环杂芳基与一个非芳香环稠合形成的8至10元双环杂芳基;其中,所述的非芳香环为3至6元饱和或部分不饱和单环杂环烷基或3至6元饱和或部分不饱和单环环烷基;所述的5或6元单环杂芳基选自:噻吩、N烷基吡咯烷酮、呋喃、噻唑、异噻唑、咪唑、噁唑、吡咯、吡唑、三唑、1,2,3-三唑、1,2,4-三唑、1,2,5-三唑、1,3,4-三唑、四唑、异噁唑、噁二唑、1,2,3-噁二唑、1,2,4-噁二唑、1,2,5-噁二唑、1,3,4-噁二唑、噻二唑、吡啶、哒嗪、嘧啶或吡嗪;所述的3至6元饱和或部分不饱和单环杂环烷基选自:氮丙环、环氧乙烷、氮杂环丁烷、氮杂环丁烷-2-酮、氧杂环丁烷、氧杂环丁烷-2-酮、恶唑烷、吡咯烷-2-酮、吡咯烷-2,5-二酮、1,3-二氧戊环、二氢呋喃-2(3H)-酮、二氢呋喃-2,5-二酮、哌啶-2-酮、哌啶-2,6-二酮、四氢-2H-吡喃-2-酮、咪唑烷、四氢呋喃、四氢噻吩、四氢吡咯、1,3-二氧戊环-2-酮、恶唑烷-2-酮、咪唑烷-2-酮、哌啶、哌嗪、哌嗪-2-酮、吗啉、吗啉-3-酮、吗啉-2-酮、硫代吗啉-3-酮1,1-二氧化物、硫代吗啉、硫代吗啉-1,1-二氧化物、四氢吡喃、1,2-二氢氮杂环丁二烯、1,2-二氢氧杂环丁二烯、2,5-二氢-1H-吡咯、2,5-二氢呋喃、2,3-二氢呋喃、2,3-二氢-1H-吡咯、3,4-二氢-2H-吡喃、1,2,3,4-四氢吡啶、3,6-二氢-2H-吡喃、1,2,3,6-四氢吡啶、1,3-恶嗪烷、六氢嘧啶、1,4-二恶烷、四氢嘧啶-2(1H)-酮、1,4-二恶烷-2-酮、5,6-二氢-2H-吡喃-2-酮;所述的3至6元饱和或部分不饱和单环环烷基选自:环丙基、环丁基、环戊基、环戊烯基、环己基、环己烯基、环己二烯基、环丁酮、环丁烷-1,2-二酮、环戊酮、环戊烷-1,3-二酮、环己酮、环己烷-1,3-二酮;所述8至10元双环杂芳基为未取代的或被1、2、3或4个各自独立地选自S组取代基所取代。
- 如权利要求1所述的化合物、或其药学上可接受的盐、立体异构体、溶剂化合物或前药,其特征在于,R 0中,所述的5至14元杂环烷基为5至6元杂环烷基;其中,所述5至6元杂环烷基选自:恶唑烷、吡咯烷-2-酮、吡咯烷-2,5-二酮、1,3-二氧戊环、二氢呋喃-2(3H)-酮、二氢呋喃-2,5-二酮、哌啶-2-酮、哌啶-2,6-二酮、四氢-2H-吡喃-2-酮、咪唑 烷、四氢呋喃、四氢噻吩、四氢吡咯、1,3-二氧戊环-2-酮、恶唑烷-2-酮、咪唑烷-2-酮、哌啶、哌嗪、哌嗪-2-酮、吗啉、吗啉-3-酮、吗啉-2-酮、硫代吗啉-3-酮1,1-二氧化物、硫代吗啉、硫代吗啉-1,1-二氧化物、四氢吡喃、1,2-二氢氮杂环丁二烯、1,2-二氢氧杂环丁二烯、2,5-二氢-1H-吡咯、2,5-二氢呋喃、2,3-二氢呋喃、2,3-二氢-1H-吡咯、3,4-二氢-2H-吡喃、1,2,3,4-四氢吡啶、3,6-二氢-2H-吡喃、1,2,3,6-四氢吡啶、1,3-恶嗪烷、六氢嘧啶、1,4-二恶烷、四氢嘧啶-2(1H)-酮、1,4-二恶烷-2-酮、5,6-二氢-2H-吡喃-2-酮;所述5至6元杂环烷基为未取代的或被1、2、3或4个各自独立地选自S组取代基所取代。
- 如权利要求1所述的化合物、或其药学上可接受的盐、立体异构体、溶剂化合物或前药,其特征在于,R 0为取代或未取代的苯基、取代或未取代的吡啶基、取代或未取代的吡唑基或取代或未取代的四氢吡咯基;所述的“取代”是指基团中的1、2、3或4个氢原子被各自独立地选自S组取代基所取代。
- 如权利要求1所述的化合物、或其药学上可接受的盐、立体异构体、溶剂化合物或前药,其特征在于,式(I)化合物选自表A结构。
- 一种药物组合物,所述药物组合物包括权利要求1至12中任一项所述的化合物、或其药学上可接受的盐、立体异构体、溶剂化物或前药;以及药学可接受的载体。
- 如权利要求1至12中任一项所述的化合物、或其药学上可接受的盐、立体异构体、溶剂化物或前药或如权利要求13所述药物组合物在制备预防和/或治疗疾病的药物中的用途,所述疾病选自:中风、炎症性肠病,溃疡性结肠炎,克罗恩病,牛皮癣,类风湿性关节炎,NASH和心力衰竭。
- 如权利要求1至12中任一项所述的化合物、或其药学上可接受的盐、立体异构体、溶剂化物或前药或如权利要求13所述药物组合物作为制备RIPK1选择性抑制剂的用途,所述RIPK1选择性抑制剂用于治疗RIPK1相关疾病或病症。
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020227031062A KR20220141321A (ko) | 2020-02-13 | 2021-02-09 | 다이하이드로나프티리딘온 화합물, 이의 제조 방법 및 이의 의학적 용도 |
CN202180014761.0A CN115135648B (zh) | 2020-02-13 | 2021-02-09 | 二氢萘啶酮类化合物,其制法与医药上的用途 |
CA3167847A CA3167847A1 (en) | 2020-02-13 | 2021-02-09 | Dihydronaphthyridinone compound, and preparation method therefor and medical use thereof |
AU2021219832A AU2021219832B9 (en) | 2020-02-13 | 2021-02-09 | Dihydronaphthyridinone compound, and preparation method therefor and medical use thereof |
JP2022549239A JP7441477B2 (ja) | 2020-02-13 | 2021-02-09 | ジヒドロナフチリドン系化合物、その調製方法及び医薬への使用 |
US17/799,637 US20230139111A1 (en) | 2020-02-13 | 2021-02-09 | Dihydronaphthyridinone compound, and preparation method therefor and medical use thereof |
BR112022016124A BR112022016124A2 (pt) | 2020-02-13 | 2021-02-09 | Composto de di-hidronaftiridinona, e método de preparação para este e uso médico deste |
MX2022009898A MX2022009898A (es) | 2020-02-13 | 2021-02-09 | Compuesto de dihidronaftiridinona y metodo de preparacion del mismo y uso medico del mismo. |
EP21754262.0A EP4105216A4 (en) | 2020-02-13 | 2021-02-09 | DIHYDRONAPHTHYRIDINONE COMPOUND, METHOD FOR THE PRODUCTION THEREOF AND MEDICAL USE THEREOF |
ZA2022/09741A ZA202209741B (en) | 2020-02-13 | 2022-08-31 | Dihydronaphthyridinone compound, and preparation method therefor and medical use thereof |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010090252.3 | 2020-02-13 | ||
CN202010090252 | 2020-02-13 | ||
CN202110070075 | 2021-01-19 | ||
CN202110070075.7 | 2021-01-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021160109A1 true WO2021160109A1 (zh) | 2021-08-19 |
Family
ID=77291388
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2021/076160 WO2021160109A1 (zh) | 2020-02-13 | 2021-02-09 | 二氢萘啶酮类化合物,其制法与医药上的用途 |
Country Status (12)
Country | Link |
---|---|
US (1) | US20230139111A1 (zh) |
EP (1) | EP4105216A4 (zh) |
JP (1) | JP7441477B2 (zh) |
KR (1) | KR20220141321A (zh) |
CN (1) | CN115135648B (zh) |
AU (1) | AU2021219832B9 (zh) |
BR (1) | BR112022016124A2 (zh) |
CA (1) | CA3167847A1 (zh) |
MX (1) | MX2022009898A (zh) |
TW (1) | TWI779487B (zh) |
WO (1) | WO2021160109A1 (zh) |
ZA (1) | ZA202209741B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023011428A1 (zh) * | 2021-08-02 | 2023-02-09 | 劲方医药科技(上海)有限公司 | Ripk1抑制剂的晶型及其酸式盐和其酸式盐的晶型 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011076734A1 (en) * | 2009-12-21 | 2011-06-30 | Euroscreen S.A. | Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases |
WO2011076732A1 (en) * | 2009-12-21 | 2011-06-30 | Euroscreen S.A. | Compounds, pharmaceutical composition and methods for use in treating gastrointestinal disorders |
WO2013147649A2 (ru) * | 2012-03-29 | 2013-10-03 | ХОЛИН, Максим Николаевич | ИНГИБИТОРЫ СИГНАЛЬНОГО ПУТИ PI3K/AKT/IKK/NF-kB, ИХ ФАРМАЦЕВТИЧЕСКИ ПРИЕМЛЕМЫЕ СОЛИ И СОДЕРЖАЩИЕ ИХ КОМПОЗИЦИИ ДЛЯ ПРОФИЛАКТИКИ И ЛЕЧЕНИЯ ВИРУСНЫХ ЗАБОЛЕВАНИЙ |
CN105916503A (zh) * | 2014-01-14 | 2016-08-31 | 米伦纽姆医药公司 | 杂芳基化合物和其用途 |
CN110325526A (zh) * | 2017-02-28 | 2019-10-11 | 伊莱利利公司 | 异喹啉和萘啶化合物 |
WO2020192562A1 (zh) * | 2019-03-22 | 2020-10-01 | 劲方医药科技(上海)有限公司 | 取代的杂环酰胺类化合物,其制法与医药上的用途 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2011003239A (es) * | 2008-09-26 | 2011-04-28 | Merck Sharp & Dohme | Nuevos derivados de bencimidazol ciclicos utiles como agentes anti-diabeticos. |
WO2010052222A1 (en) * | 2008-11-07 | 2010-05-14 | Evotec Neurosciences Gmbh | (dihydro)naphthyridinone derivatives as histamine h3 receptor antagonists |
KR102549952B1 (ko) * | 2017-02-13 | 2023-06-29 | 브리스톨-마이어스 스큅 컴퍼니 | 키나제 억제제로서의 아미노트리아졸로피리딘 |
-
2021
- 2021-02-09 CN CN202180014761.0A patent/CN115135648B/zh active Active
- 2021-02-09 US US17/799,637 patent/US20230139111A1/en active Pending
- 2021-02-09 CA CA3167847A patent/CA3167847A1/en active Pending
- 2021-02-09 AU AU2021219832A patent/AU2021219832B9/en active Active
- 2021-02-09 WO PCT/CN2021/076160 patent/WO2021160109A1/zh active Application Filing
- 2021-02-09 MX MX2022009898A patent/MX2022009898A/es unknown
- 2021-02-09 BR BR112022016124A patent/BR112022016124A2/pt unknown
- 2021-02-09 JP JP2022549239A patent/JP7441477B2/ja active Active
- 2021-02-09 KR KR1020227031062A patent/KR20220141321A/ko unknown
- 2021-02-09 TW TW110105011A patent/TWI779487B/zh active
- 2021-02-09 EP EP21754262.0A patent/EP4105216A4/en active Pending
-
2022
- 2022-08-31 ZA ZA2022/09741A patent/ZA202209741B/en unknown
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011076734A1 (en) * | 2009-12-21 | 2011-06-30 | Euroscreen S.A. | Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases |
WO2011076732A1 (en) * | 2009-12-21 | 2011-06-30 | Euroscreen S.A. | Compounds, pharmaceutical composition and methods for use in treating gastrointestinal disorders |
WO2013147649A2 (ru) * | 2012-03-29 | 2013-10-03 | ХОЛИН, Максим Николаевич | ИНГИБИТОРЫ СИГНАЛЬНОГО ПУТИ PI3K/AKT/IKK/NF-kB, ИХ ФАРМАЦЕВТИЧЕСКИ ПРИЕМЛЕМЫЕ СОЛИ И СОДЕРЖАЩИЕ ИХ КОМПОЗИЦИИ ДЛЯ ПРОФИЛАКТИКИ И ЛЕЧЕНИЯ ВИРУСНЫХ ЗАБОЛЕВАНИЙ |
CN105916503A (zh) * | 2014-01-14 | 2016-08-31 | 米伦纽姆医药公司 | 杂芳基化合物和其用途 |
CN110325526A (zh) * | 2017-02-28 | 2019-10-11 | 伊莱利利公司 | 异喹啉和萘啶化合物 |
WO2020192562A1 (zh) * | 2019-03-22 | 2020-10-01 | 劲方医药科技(上海)有限公司 | 取代的杂环酰胺类化合物,其制法与医药上的用途 |
Non-Patent Citations (39)
Title |
---|
CELL DEATH DIS, vol. 2, 2011, pages e230 |
CELL DEATH DIS., 2011, pages 2e115 |
CELL HOST&MICROBE, vol. 15, 2014, pages 23 - 35 |
CELL, vol. 137, 2009, pages 1100 - 1111 |
CELL, vol. 153, 2013, pages 1 - 14 |
CHEM. RES., vol. 37, 2012, pages 1849 - 1858 |
CLAPS, PROC. NATL. ACAD. SCI. USA., vol. 105, 2008, pages 11778 - 11783 |
CURR. BIOL, vol. 9, 1999, pages 539 - 542 |
DAI, EMBO REP, vol. 10, 2009, pages 916 - 922 |
FAS, J. BIOL. CHEM., vol. 279, 2004, pages 7925 - 7933 |
FASTNFR-1, CELL, vol. 81, 1995, pages 513 - 523 |
FEBS J, vol. 278, 2012, pages 877 - 887 |
GAUCHER, NATURE MEDICINE ADVANCE ONLINE PUBLICATION, 19 January 2014 (2014-01-19) |
GENES DEV., vol. 27, 2013, pages 1640 - 1649 |
GREENWALD, R.BCHOE, YHCONOVER, C.DSHUM, KWU, DROYZEN, M, J. MED. CHEM., vol. 43, 2000, pages 475 |
IMMUNITY, vol. 35, 2011, pages 908 - 918 |
IMMUNITY, vol. 4, 1996, pages 387 - 396 |
J. BIOL. CHEM., vol. 274, 1999, pages 16871 - 16875 |
J. NEUROSCI. RES., vol. 88, 2010, pages 1569 - 1576 |
KIDNEY INT., vol. 81, 2012, pages 751 - 761 |
MLKLPGAM5, CELL, vol. 148, 2012, pages 228 - 243 |
NAT. CHEM. BIOL., vol. 1, 2005, pages 112 - 119 |
NAT. REV. IMMUNOL, vol. 8, 2008, pages 279 - 289 |
NATURE, vol. 477, 2011, pages 330 - 334 |
PNAS, vol. 107, 2010, pages 21695 - 21700 |
PROC. NATL. ACAD. SCI. USA., vol. 109, 2012, pages 5322 - 5327 |
PROC. NATL. ACAD. SCI., vol. 109, no. 36, 2012, pages 14598 - 14603 |
REN. FAIL., vol. 34, 2012, pages 373 - 377 |
RIP1, MOL. CELL, vol. 22, 2006, pages 245 - 257 |
SAULNIER, M.GFRENNESSON, D.BDESHPANDE, M.SHANSEL, S.BVYSA, D.M.BIOORG, MED.CHEM LETT, vol. 4, 1994, pages 1985 - 1990 |
See also references of EP4105216A4 |
TLR3, NAT IMMUNOL., vol. 5, 2004, pages 503 - 507 |
TLR4, J. BIOL. CHEM., vol. 280, 2005, pages 36560 - 36566 |
TNFR1, CELL, vol. 114, 2003, pages 181 - 190 |
TRADD, NAT. IMMUNOL, vol. 9, 2008, pages 1037 - 1046 |
TRAF2/5, J. MOL. BIOL., vol. 396, 2010, pages 528 - 539 |
TRAIL, CELLSIGNAL, vol. 27, no. 2, February 2015 (2015-02-01), pages 306 - 14 |
TRAIL-R1TRAIL-R2, IMMUNITY, vol. 7, 1997, pages 821 - 830 |
TRENDS BIOCHEM. SCI., vol. 30, 2005, pages 151 - 159 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023011428A1 (zh) * | 2021-08-02 | 2023-02-09 | 劲方医药科技(上海)有限公司 | Ripk1抑制剂的晶型及其酸式盐和其酸式盐的晶型 |
Also Published As
Publication number | Publication date |
---|---|
CA3167847A1 (en) | 2021-08-19 |
CN115135648A (zh) | 2022-09-30 |
JP2023513825A (ja) | 2023-04-03 |
AU2021219832B9 (en) | 2024-02-15 |
MX2022009898A (es) | 2022-08-25 |
ZA202209741B (en) | 2023-04-26 |
AU2021219832A1 (en) | 2022-09-29 |
CN115135648B (zh) | 2024-02-09 |
AU2021219832B2 (en) | 2024-01-25 |
EP4105216A1 (en) | 2022-12-21 |
US20230139111A1 (en) | 2023-05-04 |
KR20220141321A (ko) | 2022-10-19 |
TWI779487B (zh) | 2022-10-01 |
JP7441477B2 (ja) | 2024-03-01 |
EP4105216A4 (en) | 2024-02-28 |
BR112022016124A2 (pt) | 2022-10-25 |
TW202140476A (zh) | 2021-11-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110818724B (zh) | 吡啶酮和氮杂吡啶酮化合物及使用方法 | |
WO2020216371A1 (zh) | Egfr抑制剂及其应用 | |
TWI747846B (zh) | 苯內醯胺化合物 | |
WO2022228568A1 (zh) | 吡啶或嘧啶并环类化合物,其制法与医药上的用途 | |
TW202128701A (zh) | 取代的雜環并環類化合物,其製法與醫藥上的用途 | |
CN112585139A (zh) | 用作t细胞激活剂的萘啶酮化合物 | |
CN107820494B (zh) | 核受体调节剂 | |
WO2021239058A1 (zh) | 稠合三环类化合物、其药物组合物及用途 | |
WO2019174533A1 (zh) | Pd-1/pd-l1类小分子抑制剂及其在药物中的应用 | |
KR20200101956A (ko) | 6-아자인돌 화합물 | |
CN111819176A (zh) | 4-氮杂吲哚化合物 | |
CA3131337C (en) | Substituted heterocyclic amide compound and preparation method therefor and pharmaceutical use thereof | |
TW201506018A (zh) | 二雜芳基化合物及其用途 | |
CN115515949A (zh) | 新型氨基嘧啶类egfr抑制剂 | |
CN110088100A (zh) | 作为cdc7抑制剂的嘧啶酮衍生物 | |
TWI779487B (zh) | 二氫萘啶酮類化合物,其製法與醫藥上的用途 | |
WO2023041049A1 (zh) | 作为sos1抑制剂的杂环化合物及其用途 | |
RU2809869C1 (ru) | Соединение на основе дигидронафтиридинона, и способ его получения, и его применение в медицине | |
WO2023131122A1 (zh) | 稠环取代的六元杂环化合物及其制法和用途 | |
WO2022258052A1 (zh) | 杂环内酰胺类化合物,其制法与医药上的用途 | |
WO2023165581A1 (zh) | 一种吡啶类衍生物及其用途 | |
WO2024027712A1 (zh) | 含氮杂环类化合物、其制备方法及其应用 | |
CN114761406A (zh) | 用于治疗自身免疫性疾病的氢吡啶并[1,2-a]吡嗪化合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21754262 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3167847 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2022549239 Country of ref document: JP Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112022016124 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 20227031062 Country of ref document: KR Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2021754262 Country of ref document: EP Effective date: 20220913 |
|
ENP | Entry into the national phase |
Ref document number: 2021219832 Country of ref document: AU Date of ref document: 20210209 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 112022016124 Country of ref document: BR Kind code of ref document: A2 Effective date: 20220812 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 522440081 Country of ref document: SA |